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Abstracts
Adiponectin and Alzheimer’s disease
A. Baranowska-Bik
Centre of Postgraduate Medical Education, Department of 
Endocrinology, Warsaw, Poland
Adipokines could influence physiological processes 
including energy expenditure, insulin sensitivity and 
secretion, glucose and lipid metabolism and many 
others. Adiposity is associated with an unfavorable pat-
tern of adipokines that results in enhanced morbidity of 
type 2 diabetes, hyperlipidemia, hypertension and car-
diovascular disease. The role of metabolic disturbances 
and adiposity in the development of neurodegenera-
tion found in Alzheimer’s disease (AD), the main cause 
of memory impairment in elderly, has been discussed. 
T Interestingly, AD is characterized by the central 
functional hypoglycemia and hypometabolism. Insulin 
resistance occurring in the CNS of AD patients was 
named Type 3 Diabetes (T3D). Adiponectin possesses 
an anti-inflammatory and metabolism regulating pro-
perties. There is also a link between peripheral adipo-
nectin activity and insulin/insulin resistance. Therefore, 
it seems to be important to assess whether adiponectin 
fractions in combination with metabolic parameters, 
especially insulin and insulin resistance, correlate 
with the stage of AD. Our data reporting changes in 
adiponectin profile in AD indicate a possible correlation 
between adiponectin variations and dementia. We hy-
pothesize that these changes result from compensatory 
mechanism against neuropathological processes, as well 
as from adiponectin homeostasis impairment.
Adipsic diabetes insipidus in patient after 
resection of craniopharyngioma
A. Baranowska-Bik1, M. Waszkiewicz-Hanke2,  
W. Zgliczyński1
1Centre of Postgraduate Medical Education, Department of 
Endocrinology, Warsaw, Poland
2Bielański Hospital, Department of Endocrinology, Warsaw, Poland
Introduction: Diabetes insipidus is common amongst 
patients after neurosurgery treatment of craniopha-
ryngioma, and untreated leads to severe fluid and 
electrolyte imbalance. 
We aim to present a case of adipsic diabetes insipidus 
after resection of craniopharyngioma.
57-years old woman after operation 1 year before, was 
admitted to the hospital due to recurrent hypernatremia, 
altered consciousness and psychomotor retardation. She 
had a multihormonal pituitary insufficiency. No history 
of polyuria and polydipsia was reported on desmo-
pressin treatment (60 mcg every other day). The blood 
test showed serum Na concentration of 158 mmol/L, 
plasma osmolality 346 mOsm/kg, creatinine concen-
tration 1,57 mg/dL. The patient was treated with fluids 
i.v., fluid balance monitoring was carried out. The dose 
of desmopressin was increased to 60 mcg twice a day. 
The patient was instructed to keep a low-sodium diet 
and drink an adequate amount of water. A significant 
improvement in the clinical status, normalization of 
sodium, osmolality, renal function were achieved. After 
discharge, frequent ambulatory visits were required. 
To sum up, both polydipsic and adipsic diabetes insi-
pidus in patients after craniopharyngioma treatment. 
Damage of the thirst center in the hypothalamus and 
abnormal thirst response to osmotic stimuli results in 
an absence of polydipsia and polyuria. An assessment 
of sodium concentration and plasma osmolality seem 
to be beneficial for this group of patients.
Suprasellar lipoma
A. Baranowska-Bik1, M. Waszkiewicz-Hanke2,  
W. Zgliczyński1
1Centre of Postgraduate Medical Education, Department of 
Endocrinology, Warsaw, Poland
2Bielański Hospital, Department of Endocrinology, Warsaw, Poland
Introduction: Intracranial lipomas are congenital le-
sions found at any age. They represent less than 0.1% 
of all intracranial tumors. This kind of tumor could be 
asymptomatic or symptoms include epilepsy, heada-
ches, behavioral changes, and cranial nerve paralysis. 
We aim to present a case of suprasellar lipoma. 
30 years old man with a suprasellar mass is under con-
trol of our Endocrinology Department. He had an MRI 
scan of the central nervous system because of severe 
headaches with fainting. MRI scan revealed the supra-
sellar tumor, 14 x 15 x 12 mm, described as a homoge-
nous mass traversed by the small vessels, compressing 
the right half of the optic chiasm and pituitary stalk. At 
the time of diagnosis hormonal function of the hypo-
thalamic-pituitary axis was intact. The patient showed 
a visual field defect with right-side temporal abnor-
malities. There was no indication for a neurosurgical 
intervention at that time. According to the MRI cha-
racteristics he was diagnosed with suprasellar lipoma. 
Because of no available evidence-based guidelines for 
the management of such rare suprasellar tumors, it was 
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decided to assess the patient’s visual field and hormonal 
status every 6 months and MRI of the hypothalamic-
-pituitary region every 12 months. Up to date, the follow 
up has been continued for 30 months. The MRI scans 
revealed a stable image of the tumor. The patient did 
not show significant deterioration in the visual field, the 
hypothalamic-pituitary axis function was preserved.
Neuropeptide B stimulates insulin expression 
and secretion but not proliferation and cell 
death in INS-1E cells
M. Billert, M. Skrzypski, T. Wojciechowicz,  
M. Jasaszwili, J. Waśko, K.W. Nowak
Poznan University of Life Sciences, Department of Animal Physiology 
and Biochemistry, Poznan, Poland
Introduction: Neuropeptide B (NPB) modulates appeti-
te, body weight and energy homeostasis by interacting 
with G-protein coupled receptors termed as NPBW1 and 
NPBW2 (GPR7 and GPR8). Humans express both types 
of receptors, while rodents express NPBW1, only. NPB 
and NPBW1 are widely expressed in central nervous 
system and in peripheral tissues including pancreatic 
islets. Although recent animal studies revealed the pro-
minent role of NPB and NPBW1 in controlling energy 
homeostasis and metabolism, the role of NPB in con-
trolling pancreatic beta cell functions remain unknown.
The aim of this study was to characterize the effects 
of NPB on insulin expression and secretion in insulin 
producing INS-1E cells. Furthermore, the role of NPB 
in modulation of INS-1E cell proliferation, viability and 
death was evaluated.
The experiments were conducted on rat INS-1E cells 
(beta cell surrogate). Gene expression was assessed 
by real-time PCR. Cell proliferation and viability were 
determined by BrdU and MTT tests, respectively. Cell 
death was studied by evaluation of histone-complexed 
DNA fragments (mono- and oligonucleosomes).
The results of this study show that NPB stimulates in-
sulin mRNA expression and secretion. By contrast, NPB 
fails to affect INS-1E cell proliferation, viability and death. 
In conclusion, this data show that NPB may regulate 
energy homeostasis by stimulation of insulin neogene-
sis and secretion. 
Olfactory neuroblastoma diagnosed 
in a patient with chronic syndrome of 
inappropriate antidiuretic hormone secretion
I. Czajka-Oraniec, W. Zgliczyński
Centre of Postgraduate Medical Education, Endocrinology Department, 
Warsaw, Poland
The syndrome of inappropriate antidiuretic hor-
mone secretion (SIADH) is frequently related to 
malignancies. Most commonly it was reported in small 
cell lung cancer but association with many carcinomas 
and neuroendocrine tumours was described. To date, 
18 cases of SIADH induced by olfactory neuroblastoma 
have been published. 27-year-old woman presented 
with 12-years history of severe hyponatremia in the 
course of idiopathic SIADH. She has been hospitalized 
many times because of recurrent symptoms (headache, 
nausea, vomiting, abdominal pain) of hyponatremia and 
hypoosmolality with high ADH level. She was treated 
with water restriction, furosemide, fludrocortisone or 
hydrocortisone. We performed further thorough exami-
nation and MRI revealed pathological mass in left nasal 
cavity and maxillary sinus. Patient suffered occasionally 
from epistaxis and nose congestion attributed to chronic 
sinusitis. 68Ga-DOTA-TATE PET/CT showed increased 
somatostatin receptor (SSR) expression in that mass. The 
biopsy result was olfactory neuroblastoma. The complete 
resection of the tumour that originated in ethmoid sinus 
was performed. She also received adjuvant radiotherapy. 
Immediately after surgery sodium concentration norma-
lized and patient is normonatremic for almost 2 years 
since then. In all cases of SIADH thorough examination 
and searching for malignancy is essential. Even in long 
lasting idiopathic SIADH repeated imaging is necessary. 
SSR PET/CT could be helpful in such cases.
The effect of neurokinin A and B on in vitro 
prolactin secretion by anterior pituitary cells of 
cyclic gilts
W. Czelejewska, S. Okrasa
Department of Animal Anatomy and Physiology, Faculty of Biology and 
Biotechnology, University of Warmia and Mazury in Olsztyn, Olsztyn, 
Poland
Introduction: Neurokinins participate in the regulation 
of reproductive functions, acting at three different levels 
of the hypothalamo-pituitary-gonadal axis. Our pre-
vious studies indicated that neurokinin A (NKA) and B 
(NKB) are synthesized in the porcine anterior pituitary 
and affect the expression of PRL, TRHR and D2R genes. 
The aim of the current study was to determine the influ-
ence of NKA and NKB on in vitro prolactin secretion by 
porcine anterior pituitary cells during the estrous cycle.
Cells isolated from anterior pituitaries of gilts on days 
8–10, 15–16 and 18–20 (n = 3 × 5) of the estrous cycle 
were incubated for 4 h with NKA and NKB (at doses 
10–7, 10–8, 10–9 mol/L) alone or in combination with 
TRH or dopamine. Radioimmunoassay was performed 
to determine prolactin concentration in media collected 
after in vitro culture. 
The results did not reveal any influence of NKA and 
NKB on basic prolactin secretion on examined days 
of the estrous cycle. However, we noted significantly 
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higher (p < 0.05) prolactin secretion on days 18–20 after 
treatment with NKB in combination with TRH. Further-
more, we observed a tendency (p < 0.08) to stimulation 
prolactin release by NKA in the presence of dopamine 
on days 15–16 of the estrous cycle. 
In conclusion, presented data imply that neurokinins 
may be involved in the modulation of prolactin secre-
tion at the pituitary level by affecting the responsive-
ness of lactotrophs to hypothalamic factors, involved 
in the control of its release, i.e. dopamine and TRH.
This Research was financed by National Science Centre, 
Poland, Grant No. 2016/21/N/NZ9/02301.
Plasma omentin and visfatin in patients 
with systemic sclerosis — the preliminary 
investigation
K. Dopytalska1, W. Bik2, M. Wieczorek1, M. Kalisz2,  
A. Litwiniuk2, B. Baranowska3, I. Walecka-Herniczek1
1Centre of Postgraduate Medical Education, Department of 
Dermatology, Warsaw, Poland
2Centre of Postgraduate Medical Education, Department of 
Neuroendocrinology, Warsaw, Poland 
3Warsaw Medical University, Department of Neurology, Second Faculty 
of Medicine, Poland 
Introduction: Systemic sclerosis (SSc) is an autoimmu-
ne chronic disease characterized by vasculopathy and 
fibrosis of the skin and internal organs. The origin of 
this disease is still unknown but the latest studies sho-
wed a possible role of adipokines in the development 
of fibrosis in the course of SSc. Adipokines may act also 
as a modulator of the immune response and fibrosis.
The aim of our study was to evaluate the changes 
in plasma leptin levels of omentin and visfatin and 
HOMA-IR in patients suffering from SSc.
30 patients with SSc (age 51 ± 13; BMI 23.4 ± 2.9) and 
12 healthy (age 35 ± 8; BMI 22.6 ± 2.8) were enrolled 
to the study. The severity of the skin fibrosis was 
evaluated using the Rodnan scale. In all participants, 
plasma omentin and visfatin were assessed using ELISA 
method as well as HOMA-IR was calculated. 
Results: Plasma omentin levels and HOMA-IR were 
significantly higher in patients with SSc compared with 
control group. Patients with a duration of disease more 
than 10 years presented the highest levels of omentin. 
Omentin levels negatively correlated with the Rodnan 
scale. We did not notice the significant differences be-
tween patients with long-lasting SSc (> 10 yrs.) with 
respect to those who suffered less than 10 yrs. Our data 
did not reveal any changes in plasma visfatin levels. 
To sum up, omentin may be a potential metabolic mar-
ker in a course of systemic sclerosis.
This study was supported by CMKP grant 506-1-31-22-18.
BMP (bone morphogenetic proteins) system 
activity in the anterior pituitary gland
A. Gajewska
Department of Animal Physiology, The Kielanowski Institute of Animal 
Physiology and Nutrition PAS, Jablonna n. Warsaw, Poland
Introduction: BMPs are secreted signaling molecules 
belonging to the transforming growth factor-β (TGF-β) 
superfamily known for its role in the regulation of an-
terior pituitary activity.
The aim of this study was to determine whether central 
(GnRH) and peripheral (17β-estradiol) affect selected 
BMPs transcription in anterior pituitary gland in vivo. 
The experiment was conducted on ovariectomized 
4 month old rats which received central (1 pulse/h/over 
5h) microinjections of 1.5 nM GnRH; 2 nM GnRHR 
ant + 1.5 nM GnRH; 0.9% NaCl (controls) or, sc injections 
of 17β-estradiol (3x20 μg/0.2 mL), PPT (ESR1 agonist; 3x 
0.5 mg/0.2 mL), DPN (ESR2 agonist; 3 x 0.5 mg/0.2 mL 
and in controls, 3 x 0.2 mL DMSO.
qRTPCR method was applied to evaluate BMP2, BMP4, 
BMP6, BMP7, BMP15, BMPRIA, BMPRIB, BMPR2, 
Smad1, Smad5, Smad8 mRNA expression. 
The results indicated that GnRH up-regulated BMP2, 
BMP-15, and BMPR-IA mRNA expression as well as 
BMPs signaling pathway transcription factors Smad1 and 
Smad5 mRNA levels. Contrary, estrogen down-regu-
lated BMPs system activity. A decreased BMP2 and 
BMP-6 mRNA level resulted from ESR1 stimulation whe-
reas reduced BMP-15transcription required ESR1and 
ESR2 activity. BMPR-1A and BMPR2 mRNA level was 
diminished in an ESR1-dependent manner Both estrogen 
receptors promoted decrease of Smad5 transcription.
In conclusion, obtained data suggest that BMPs activity 
depends on GnRH and estrogenic inputs exerted in 
a gene-specific manner at the BMPs network trans-
criptional level. 
Research was financed by The Kielanowski Institute 
of Animal Physiology and Nutrition statutory activity: 
project III.2.3/2017. 
The diagnosis and treatment of pituitary 
insufficiency in adults
A. Gilis-Januszewska, A. Hubalewska-Dydejczyk
Department of Endocrinology, Jagiellonian University, Collegium 
Medicum, Krakow, Poland 
Hypopituitarism is characterized by clinical symp-
toms of a deficiency of one or more hormones of the 
pituitary gland which can result from diseases of the 
pituitary gland or the hypothalamus. The prevalence of 
hypopituitarism 50 cases/100000 individuals probably 
underestimates the actual incidence, given that as many 
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as 30–40% of people with traumatic brain injury (TBI) 
might present impaired pituitary function. Mortality 
is increased by 1.3- to 2.2-fold compared with age- and 
sex-matched cohorts.
Hypopituitarism can be congenital or acquired. In 
adults the most common causes include intracranial 
tumors (including pituitary and hypothalamic tumors), 
neurosurgery, irradiation to head region, postpartum 
pituitary necrosis, cerebrovascular accidents, granulo-
matous or autoimmune hypophysitis, sarcoidosis and 
pituitary abscess. There is a growing evidence of the 
hypopituitarism found after TBI and other traumas 
including contact sports trauma (up to 49%), ischemic 
stroke (17%), patients with subarachnoid hemorrhage 
(up to 47%), surgeries eg. cardiosurgery or pituitary in-
flammation after new biological therapies. The clinical 
manifestations of hypopituitarism depend on the type 
and degree of hormone deficiency and the rapidity of 
its onset, may be non-specific and thus the diagnosis 
is often missed. The diagnosis of hypopituitarism is 
made by examining the basal hormone levels or per-
forming stimulation tests in some cases. Replacement 
treatment exists in the form of thyroxine, hydrocortiso-
ne, sex steroids, growth hormone, and desmopressin. 
Modifications in replacement treatment are needed 
during the transition from pediatric/adolescence 
to adulthood, during pregnancy and stress/acute 
state. 
The aim of the presentation is to present the current 
view on the diagnosis and treatment of pituitary 
insufficiency in adults illustrated by a clinical case 
presentation. 
Diagnostics and management of growth 
hormone deficiency in childhood and 
adolescence — yesterday, today and tomorrow
M. Hilczer
Medical University of Lodz, Polish Mother`s Memorial Hospital-
Research Institute, Lodz
Department of Pediatric Endocrinology Medical University of Lodz, 
Department of Endocrinology and Metabolic Diseases, Polish Mother’s 
Memorial Hospital-Research Institute, Lodz, Poland
Growth hormone deficiency (GHD) is important cause 
of short stature in children with a prevalence of 1 in 
4000 during childhood. The diagnosis of GHD is based 
on an assessment of auxological data with supporting 
evidence from biochemical and neuroradiological 
studies. Growth hormone (GH) stimulation tests play 
a key role in GHD diagnosis but the measured GH con-
centration can vary significantly with stimulation test 
and GH assay used creating difficulties for diagnostic 
accuracy. The lack of any gold standard test for GHD 
diagnosis has led to the development of somewhat 
arbitrary cut-off levels. When GH stimulation tests 
were first used, a peak GH after stimulation < 5 ng/mL 
was used to diagnose GHD. Over time the cut-off 
has increased to 7 ng/mL and 10 ng/mL. Separating 
the group of short children with mild GH deficiency 
from non GH deficient children remains challenging. 
In this presentation I will review the data from our 
department on diagnosis of GHD — which pharmaco-
logical test to use, issues with GH and IGF-1 assays. At 
the end of presentation are news about new trends 
in the therapy of GHD children with long acting GH 
molecules.
The effect of ACTH on the expression of 
gonadotropin-inducible ovarian transcription 
factor 1 (Giot1) gene in the adrenal glands of 
the rat
K. Jopek, M. Tyczewska, M. Szyszka, P. Celichowski,  
P. Milecka, M. Rucinski, L.K. Malendowicz
Poznan University of Medical Sciences, Department of Histology and 
Embryology, Poznan, Poland
Introduction: Giot1 belongs to the fast-responsive genes 
family. In vivo, in ovaries of immature rats, the expres-
sion of this gene increases rapidly after administration 
of PMSG or hCG. Moreover, in vitro levels of mRNA 
Giot1 in Leydig cells increase significantly after addi-
tion to the medium of pMSG/hCG. Detailed mutational 
studies of Giot1 proximal promoter have identified in 
this gene a cAMP response element (CRE). 
The aim of the study was to demonstrate whether 
ACTH regulates the expression of Giot1 in adrenals and 
through which mechanism it exerts its effect. 
Acute (1h) i.p. administration of ACTH to mature 
male rats causes a rapid increase in expression of the 
Giot1 gene in ZG and ZF/R. Similar results were obtained 
in the case of chronic infusion of ACTH. In both males 
and females, gonadectomy increases the expression of 
the gene in the adrenal glands. ACTH also stimulates 
the expression of the Giot1 gene in primary culture of rat 
adrenocortical cells. In contrast to ACTH, hCG does not 
affect both the level of expression of the Giot1 gene and 
corticosterone secretion. The stimulating effect of ACTH 
on the expression of the Giot1 gene is inhibited by admi-
nistration of H-89. This suggests that the stimulating ef-
fect of ACTH on the expression of Giot1 gene is mediated 
by cAMP. 
The obtained results suggest that Giot1 may be one of 
the factors involved in the regulation of adrenal stero-
idogenesis.
This research was supported by “Diamond Grant” 
program of the Polish Ministry of Science and Higher 
Education No. 0171/DIA/2015/44.
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The influence of melatonin and forskolin on 
the hypothalamic cAMP content as well as 
oxytocin secretion from the rat hypothalamus 
and neurohypophysis in vitro
M. Juszczak1, A. Krzymińska2, E. Bojanowska3,  
M. Roszczyk1 
1Department of Pathophysiology and Experimental Neuroendocrinology, 
Chair of General and Experimental Pathology, Medical University of 
Lodz, Poland
2Department of Neuropeptides Research, Chair of General and 
Experimental Pathology, Medical University of Lodz, Poland
3Department of Behavioral Pathophysiology, Chair of General and 
Experimental Pathology, Medical University of Lodz, Poland
Introduction: The goal of the present investigation was 
to answer the question whether melatonin (MT) could 
influence the forskolin-induced accumulation of cAMP 
in the rat hypothalamus and oxytocin (OT) secretion 
from the rat hypothalamus (Hth) and neurohypophysis 
(NH) in vitro.
Material and methods: Male rats Hth and NH explants 
were separately placed in 1 mL of Krebs-Ringer buffer 
(K-RB). Each explant of Hth or NH was incubated suc-
cessively in: 1 — normal K-RB {fluid F1}, 2 — the K-RB 
as F1 supplemented with melatonin (10–7 M) and/or 
forskolin (10–5 M) or their vehicles (0.1% ethanol or 0.1% 
DMSO) {fluid F2}. After 20 min incubation, each me-
dium {F1 and F2} was collected and frozen before OT 
estimation by the RIA. At the end of incubation, the Hth 
samples were immediately placed in tubes containing 
1 mL of 0.1 M HCl, frozen and stored at –20°C until the 
content of cAMP in the Hth was estimated by the ELISA 
assay.
Results: MT significantly diminished the cAMP accu-
mulation and inhibited forskolin-induced elevation of 
the cAMP content in the rat Hth. Forskolin significantly 
increased OT secretion from the NH and Hth, while MT 
diminished basal and inhibited forskolin-stimulated OT 
release from the rat NH and Hth in vitro.
Conclusion: The present results suggest that melatonin 
employs the cAMP-dependent intracellular pathway(s) 
for its inhibitory influence on OT secretion from the rat 
Hth and NH in vitro.
This study was supported by Medical University of 
Lodz (grant No 503/6-103-01/503-61-001).
Neuroendocrine and metabolic response to 
critical illness
D. Kajdaniuk
Department of Pathophysiology and Endocrinology, School of Medicine 
with the Division of Dentistry in Zabrze, Medical University of Silesia, 
Katowice
Department of Endocrinology and Diabetology, Voivodeship Specialist 
Hospital No 3, Rybnik 
Critical diseases are defined as any life-threatening 
conditions that require the maintenance of organ 
function in order to avoid an impending death. Wi-
thout modern intensive care, the survival of critically 
ill patients is generally impossible. Critical diseases 
are an extreme form of hard physical effort. Biological 
reactions occurring in response to this condition are 
triggered immediately and on a larger scale than in 
other clinical conditions. Stress response (critical ill-
ness/life-threatening condition) involves the reaction 
of the endocrine system, including neuroendocrine 
and metabolic response. Due to intensive medical 
care, the survival of patients in previously fatal states 
has increased, but now more patients “enter” the 
chronic phase of critical illness, during which multi-
-week support/maintenance of organ functions is still 
necessary, despite the removal of factors initiating the 
critical illness. 
The topic of the lecture includes: 1. the response of 
the hypothalamus and the anterior pituitary to the 
critical illness; 2. the response of the adrenal gland to 
life-threatening conditions; 3. NonThyroidal Illness 
Syndrome pathomechanism; 4. metabolic reactions 
(mainly, carbohydrate metabolism) that occur in cri-
tically ill patients. The lecture attempted to link the 
neuroendocrine and metabolic response to critical ill-
ness. Differences between its acute and chronic phase 
were taken into account.
The influence of all-trans retinoic acid on 
adiponectin and TNF-α levels in the adipose 
tissue of ApoE mice
M. Kalisz, A. Litwiniuk, M. Chmielowska, L. Martyńska, 
E. Wasilewska-Dziubińska, W. Bik
Department of Neuroendocrinology, Centre of Postgraduate Medical 
Education, Warsaw, Poland
Introduction: Retinoids, which include naturally occur-
ring vitamin A, are physiological regulators of a number 
of essential biological processes related to atheroscle-
rosis including regulation of the lipid metabolism and 
inflammation. 
The aim of the study was to examine the influence of 
all-trans retinoic acid (atRA) on adiponectin and TNF-α 
levels in the visceral and perirenal adipose tissue of 
ApoE mice.
Material and methods: Experiments were performed in 
8 weeks old male mice: Apo-E (model of atherosclerosis) 
and C57BL/6J (control group) treated with vehicle (corn 
oil) or atRA for 8 weeks. AtRA or vehicle was admini-
strated by the stomach tube. All animals were fed on 
the normal diet. Visceral and perirenal adipose tissue 
adiponectin and TNF-α concentrations were measured 
by enzyme-linked immunosorbent assay (ELISA). 
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Results: There was no significant difference between 
adiponectin concentrations in the visceral adipose tissue 
in all group of mice. However, TNF-α concentration 
was significantly lower in Apo-E mice treated with 
atRA than the vehicle. In the perirenal adipose tissue, 
adiponectin level was found to be markedly reduced 
and TNF-α concentration was significantly increased 
in C57BL/6J mice treated with atRA than the vehicle. 
Conclusion: Our data suggest that atRA may reduce in-
flammation in the visceral adipose tissue of Apo-E mice. 
However, in the perirenal adipose tissue of C57BL/6J 
mice, atRA may increase pro-inflammatory cytokine- 
TNF-α and decrease adiponectin concentration.
This study was supported by NCN grant No. 
2015/17/N/NZ5/00331.
Non-functioning pituitary adenomas in 
a 5-year evaluation
J. Karpińska, A. Szafraniec, D. Porada, M. Lenart- 
-Lipińska, J. Tarach, B. Matyjaszek-Matuszek
Chair and Department of Endocrinology, Medical University of Lublin, 
Poland
Introduction: Clinically non-functioning pituitary ade-
nomas (NFPAs) are among the most common tumors in 
the sellar region, and their diagnosis is labor-intensive 
and cost-prohibitive and the immunohistochemistry 
does not always exhibit an actual lack of hormonal 
activity (null cell adenoma).
The aim of the study: Clinical, radiological, hormo-
nal and immunohistochemical evaluation of patients 
with NFPAs.
Material and methods: 125 patients, mean age 50 ± 18.4, 
77 women (61.6%) with diagnosed NFPAs, hospitalized 
in a period from June 2013 to May 2018 in the Clinic of 
Endocrinology, Medical University of Lublin.
A retrospective analysis of medical records of patients 
hospitalized due to NFPAs.
Results: In the radiological assessment, a predominance 
of macroadenomas (57.6%), median size 15.2 ± 11.3 mm, 
was observed. Most adenomas manifested with a com-
pression of the intersection of optic nerves (40.7%), 
sphenoidal sinus invasion 39.8%, cavernous sinus 
invasion 19.5%, (multidirectional 28.8%). Clinically 
headache (45%), dizziness and visual disturbances (27% 
each) were observed. Additionally, in 30 (24%) patients 
pituitary insufficiency was found (gonadotropic 33.8%, 
corticotrophic and thyrotropic — 22%). In the 5-year 
follow-up, 23 (18.4%) patients underwent surgery, and 
the immunohistochemistry tests showed a dominance 
of null cells, gonadotropic cells and thyrotropic cells.
Conclusions: NFPAs are usually recognized as 
macroadenomas most commonly with coexisting 
suprasellar expansion and compression on the optic 
chiasm. Clinical manifestations were a headache in 
every second patient, and one in four presented hy-
popituitarism.
Visualizing migration and activation of T cells 
in vivo
N. Kawakami
Institute of Clinical Neuroimmunology, University Hospital and 
Biomedical Center, Ludwig-Maximilians University Munich, Munich
Multiple sclerosis (MS) is an autoimmune disease which 
is characterized by inflammation in the central nervous 
system (CNS). Although the detailed pathomechanism 
of MS is still largely unknown, autoantigen specific 
encephalitogenic T cells are considered as key player. 
To visualize how these T cells migrate into the CNS and 
induce inflammation, intravital imaging of these T cells 
in the animal model for MS, Experimental Autoimmu-
ne Encephalomyelitis (EAE) was performed by using 
intravital two-photon microscopy.
The imaging revealed that the T cells appeared in the 
blood vessels at the spinal cord leptomeninges before 
onset of clinical EAE. At this stage, the T cells migrated 
on the intraluminal surface of the vessels with inte-
grin α4 dependent manner. After the extravasation 
beyond the Blood–Brain Barrier, the T cells contacted 
with phagocytes. Since the contact can induce T cell 
activation, which are known to be important to induce 
clinical EAE, T cells labelled with fluorescent protein 
based activation sensors were introduced to detect T 
cell activation in vivo. One is fluorescent resonance 
energy transfer (FRET) based calcium sensing protein, 
Twitch, and another is NFAT-GFP fusion protein. Both 
sensors successfully visualized T cell activation in vivo. 
Importantly, the intravital imaging is not applicable to 
only T cells but also other cell types, including neurons 
and glia cells.
In addition to observation of T cell migration and activa-
tion, the imaging can be used to evaluate therapeutic 
treatment. For example, the infusion of anti-integrin 
α4 antibody diminished intraluminal crawling within 
a few minutes and prevented clinical EAE completely. 
Indeed, similar antibody is used in MS patients and 
show beneficial effect. In addition, the application of 
anti-MHC class II blocking antibody or inhibitor of 
intracellular calcium signalling prevented T cell activa-
tion and ameliorated clinical EAE, revealing that T cell 
activation is critical check point to induce CNS inflam-
mation. Therefore, intravital imaging is very powerful 
tool to directly visualize cellular motility and function 
in vivo to understand the biological events as well as to 
develop therapeutic treatment.
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Abnormalities involved in intracellular growth 
signal transduction
A. Kędzia
Department of Clinical Auxology and Pediatrics Nursing, Division of 
Diabetology and Obesity of the Developmental Age, Poznan University 
of Medical Sciences, Poznan, Poland
Introduction: In recent years more and more attention 
has also been paid to irregularities in promoters of par-
ticular genes as the ones which are potentially responsi-
ble for the incorrect generation of signal factors. There 
is continuous search for irregularities of genes coding 
promoter and regulatory factors. Additionally, the focus 
is more frequent on the role of carrier proteins, such as 
GHBP and IGFBP. It is considered that a proper gene 
coding and maintaining right developmental stage-
-dependent concentrations, which results from normal 
regulation of biosynthesis, is necessary for proper 
functioning of carrier proteins. This is tightly related 
to specific nucleotide composition of promoter and 
regulatory regions. Improper binding of transcription 
factors can be a cause of low or high concentrations of 
carrier proteins, which in significant way will disturb 
time of growth hormone action, for example, IGF-I. It 
is connected with the recently emerging possibilities of 
treating also those patients in whom short stature was 
the result of molecular defects.
Results of studies indicate that there is an indisputable 
necessity of broadening the molecular diagnostic basis 
in Poland. 
Spexin as a modulator of body weight, 
metabolic and hormonal profile in obese rats
P.A. Kołodziejski, E. Pruszyńska-Oszmałek, M. Sassek, 
D. Szczepankiewicz, D. Fiksa, K.W. Nowak
Department of Animal Physiology and Biochemistry, Poznan 
University of Life Sciences, Poznan, Poland
Introduction: Spexin (SPX) is a novel, very conserva-
tive 14 amino-acids peptide discovered in 2007 using 
bioinformatics methods. SPX arises as a result of post-
-translational modifications of a prepropeptide, which 
is composed of 116 amino acid residues. It was showed 
that SPX negatively correlates with insulin resistance 
and could be involved in regulation of food intake 
behavior, neuroendocrine and metabolic functions.
The aim of the study was to investigate the effect of 
7 days SPX (35 μg/kg b.w.) administration on body 
weight, metabolic and hormonal profile in obese rats. 
We found that short term SPX administration decreased 
body weight (p < 0.05) and increased insulin sensitivity 
in rats (p < 0.01). Moreover, we noted that spexin decre-
ased serum level of ghrelin (active and total) (p < 0.05) 
and leptin (p < 0.05). Simultaneously, SPX increased 
glucagon (p < 0.05) and triiodothyronine (p < 0.01) 
concentrations in blood serum. Study of the metabolic 
profile showed that SPX decreased triglycerides level 
(p < 0.01). We did not find any effect of SPX on chole-
sterol and non-esterified fatty acids levels. Moreover, 
we investigated the effect of SPX on ALT, AST, GGTP 
and ALP activity in blood serum. We noted that SPX 
reduces the activity of investigated enzymes. 
These data indicate that spexin is a novel relevant 
player in regulation of body weight and metabolism. 
Our results suggest that SPX may be further evaluated 
as a potentially promising therapeutic target.
The study was financed by the National Science Centre, 
Poland 2015/19/N/NZ4/00572 PRELUDIUM grant and 
2017/01/X/NZ4/00466 MINIATURA grant.
All you need to know about the genetics of 
pituitary adenomas
M. Korbonits
Department of Endocrinology, William Harvey Research Institute, 
Barts and the London School of Medicine, Queen Mary University of 
London, London, United Kingdom
While just a few years ago we rarely thought about 
genetics when looking after pituitary patients, now 
this aspect of endocrinology, similar to many others, 
is keeping the genetic labs increasingly busy. Pituita-
ry adenomas with genetic origin can present as part 
of syndrome, such as MEN1&4, Carney complex, 
McCune-Albright syndrome, DICER1 syndrome and 
SDH-related syndrome, but most often they present 
as isolated disease as part of Familial Isolated Pituitary 
Adenoma (FIPA). In the FIPA group currently three 
genes have been described. (1) Heterozygous germline 
mutations in the aryl hydrocarbon receptor interacting 
protein (AIP) gene lead of young-onset mostly growth 
hormone or mixed growth hormone/prolactin-secreting 
pituitary adenomas. Due to the low (~20%) penetrance 
almost half of the AIP mutation positive patients do not 
have a known family history and present as a seemin-
gly sporadic case. (2) X-linked acrogigantism (XLAG) 
— duplication of the orphan G protein coupled receptor 
GPR101 gene, located on the X the chromosome, leads 
to infant-onset GH excess usually with concomitant 
hyperprolactinaemia. Interestingly while girls, who re-
present 80% of the known cases, usually have germline 
mutation, boys mostly have somatic mosaicism. (3) More 
recently a few cases of Cushing’s disease have been 
described with mutation in the CABLES1 (Cdk5 and 
Abl enzyme substrate 1) gene, although the importance 
of this gene needs to be confirmed. The majority of the 
FIPA families, however, have no know genetic mutation 
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and further studies are needed to identify the diseases 
causing genes in these kindreds. 
Search for somatic mutations were most successful in 
somatotrophinomas with GNAS mutations in upto 40% 
of cases, and in corticotorph adenomas with upto 30% 
(50% in females) of USB8 mutations. 
But what is the point to identify the disease causing 
genes in patients with genetic form of pituitary ade-
nomas? In syndromic diseases it may help to search 
for other manifestation of the disease; characteristics 
of the disease may help to decide on the appropriate 
treatment modalities; family members can be screened 
and followed for early diagnosis, which is a crucial po-
int in the successful treatment of pituitary adenomas; 
patients often react remarkably positively learning the 
genetic origin of their disease, it gives them a long-so-
ught explanation for the “why me?” question. Finally, 
establishing novel pathways could lead to disease-spe-
cific treatment in the future. 
Endoscopic endonasal treatment of Rathke 
cleft cysts — clinical series
J. Kunicki, W. Bonicki
Department of Neurosurgery, Center of Oncology Institute, Warsaw, 
Poland
Introduction: Rathke’s cleft cysts (RCCs) are benign 
sellar and suprasellar lesions arising from epithelial 
remnants of Rathke’s pouch. The symptomatic cases 
are treated surgically. 
The aim of the study is to evaluate endoscopic endona-
sal approaches in the management of RCCs. 
Material and methods: The study is a retrospective 
clinical series analysis. We retrospectively analyzed 
a series of 71 patients complaining of a RCC, operated 
with endoscopic transsphenoidal approach at the 
Department of Neurosurgery Center of Oncology in 
Warsaw In all cases the transsphenoidal endoscopic 
approach was performed. In 7 cases the extended ap-
proach was utilized.
Simple cyst evacuation was possible in all cases, in 
10 patients (15%) the tumor capsule was resected. In 
rest of the patients the evacuation of cyst was followed 
by capsule fenestration and biopsy of tumor capsule, 
some maneuvers to prevent it recollection. In 7 cases 
(10.1%) the extended transtuberculum sellae approach 
was used to resect suprasellar RCC.
Results: In 52 (72%) patients RCC symptoms resolved. 
The visual performance improved in 12 out of 15 cases 
with visual degradation. The most frequent complica-
tion was transient diabetes insipidus in 12 cases (16.7%), 
permanent DI was observed in 3 cases (4.1%). There was 
1 case of cerebrospinal fluid leak. During the median 
observation time of 29 months recurrence/regrowth 
occurred in in 6 patients (8.4%), only 3 cases needed 
reoperation for symptomatic recollection.
Conclusions: The endoscopic endonasal transsphe-
noidal approach for the removal of a symptomatic 
RCC is safe and effective method of treatment. The 
modification of the approach to the so called “exten-
ded” approach, allows surgical treatment of isolated 
suprasellar RCCs eliminating the need for transcra-
nial approach.
Limited–extended trans tuberculum approach 
for non-complex suprasellar hypothalamo-
pituitary pathologies — case series
J. Kunicki, W. Bonicki, P. Poppe
Department of Neurosurgery, Center of Oncology Institute, Warsaw, 
Poland
Introduction: The extended endoscopic approaches for 
suprasellar pathologies gained place in neurosurgical 
armamentarium for suprasellar pathologies. 
The aim of the study was to analyze results and com-
plications of extended transtuberculum/transplanum 
transsphenoidal approach modification called limited-
-extended approach. The modification consisted of 
limitation of approach to one nostril approach with no 
conchectomy and without use of nososeptal flap. The 
opening of the dura of suprasellar area was limited to 
sufficient minimum. The closure was performed with 
2 flattened fat tissue grafts augmented with collagen 
matrix and buttressed with titanium mesh wedged in 
bone defect. 
The study is a retrospective analysis of the use of limited 
extended suprasellar approach in 13 patients with dif-
ferent non-complex pathologies not demanding extra 
space for microdissection: 5 cases of suprasellar Rathke 
cleft cysts, 3 cases of infundibular tumors, 2 suprasellar 
pituitary adenomas, one meningioma, one chordoma, 
and one case of optic chiasm glioma. 
Results: the complete resection was achieved for all 
except optic chiasm tumor, there was a case of perma-
nent diabetes insipidus after resection of infundibular 
tumor. There was no CSF leaks, the healing of nasal 
cavity was checked after 4 weeks, only one case showed 
prolonged healing with chronic sinusitis. There was no 
nasal morbidity, no septal perforation.
The extended approach without flap and binostril 
approach can be advocated for selected non complex 
pathologies with like suprasellar cysts and small solid 
tumors not invading dural margins. The limitation of 
surgical freedom from limited exposure is not relevant 
in those pathologies. Moreover the nasal cavity he-
aling was significantly shorter and nasal complications 
were fewer.
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Clinico-pathological study of invasive 
macroadenomas with infrasellar direction of 
invasion
J. Kunicki1, M. Maksymowicz2, W. Bonicki2
1Department of Neurosurgery, Center of Oncology Institute, Warsaw, 
Poland
2Department of Pathology and Laboratory Diagnostics, Center of 
Oncology Institute, Warsaw, Poland
Introduction: Invasion of neighboring anatomical 
structures is a major factor limiting surgical efficacy. 
The infrasellar tumor invasion is regarded as one of 
factors for clinically aggressive course for adenoma. 
The purpose of the study was clinico-pathological 
evaluation of invasive pituitary adenomas with infra-
sellar invasion.
Results: Of 1072 pituitary adenomas treated at Oncologi-
cal Center from 2010 to 2017, 115 (10.8%) were reported 
as invading either: sellar floor or sphenoid sinus or cli-
vus. Adenomas with infrasellar invasion comprised 29% 
of invasive pituitary adenomas (115/378). Thirty five of the 
cases with infrasellar invasion were diagnosed as giant 
adenomas (> 4 cm). Most of the cases with infrasellar 
invasion were among non functioning pituitary adeno-
mas 67.5% (gonadotrophs-68, null cell adenomas 4, silent 
ACTH 3, silent GH 3). The infrasellar invasion coexisted 
in 55% (63/115) with invasive growth into parasellar or 
suprasellar areas. Selective infrasellar invasion was obse-
rved in 21out of 115 cases (18%) what makes 5.5% of all 
invasive adenomas. Infrasellar invasion limited effective-
ness of surgical treatment in comparison to other invasive 
tumors (21% vs 35%) Fisher exact test 0.008. 
Conclusions: Infrasellar invasion is most often coexi-
sting with other directions of invasive growth. Isolated 
infrasellar growth is rare and in majority of cases obse-
rved in prolactin secreting and non functioning adeno-
mas. The infrasellar direction of invasion if a negative 
factor for surgical resection. 
Partial agenesis of corpus callosum in a patient 
with craniopharyngioma — a very rare case 
of the co-occurrence of two diseases or 
a congenital syndrome?
M. Kurowska, J. Malicka, A. Oszywa-Chabros,  
J.S. Tarach
Department of Endocrinology, Medical University, Lublin, Poland
The aim of the study is to present a complex case of 
overlap between two rare congenital central nervous 
system diseases of an opposite nature (atrophy and 
proliferation) in a patient with pituitary insufficiency 
after previous surgical treatment due to craniopha-
ryngioma. 
Case report: A 35-year-old man with a disease dia-
gnosed at the age of 15. The first symptom of the 
tumor was increased intracranial pressure with a he-
adache, nausea and vomiting. The patient was twice 
operated (1997, 2002). After the second neurosurgery, 
persistent multi-hormonal hipopituitarism occurred, 
requiring chronic hormonal substitution. Then he 
developed metabolic syndrome with morbid obesity 
(BMI = 40.2 kg/m2), diabetes and dyslipidemia. Only 
three years ago the agenesis of two thirds of the corpus 
callosum together with the asymmetric ventricular 
system with the dominance of the left lateral ventricle 
of the brain was detected during MRI. Throughout the 
treatment period, the patient was reluctant to coope-
rate, showed lack of understanding of his own health 
situation, complained about family and medical staff 
and had an unrestrained appetite. These behaviors 
were interpreted as the effect of post-operative damage 
to the hypothalamus. 
Conclusion: Difficulties in the interpretation of 
symptoms resulting from surgery and/or concomitant 
agenesis of the corpus callosum complicate the asses-
sment of the clinical picture and treatment results in 
our patient.
Long-term subclinical Cushing’s disease in 
patient with corticotroph macroadenoma  
— case report
M. Kurowska1, J. Malicka1, A. Oszywa-Chabros1,  
G. Zieliński2, M. Maksymowicz3, J.S. Tarach1
1Department of Endocrinology Medical University of Lublin, Poland
2Department of Neurosurgery, Military Medical Institute, Warsaw, Poland
3Department of Pathology and Laboratory Diagnostics, M. Sklodowska-
Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, 
Poland 
The aim of the study is to present a clinical picture of 
a long-lasting subclinical Cushing’s disease in patient 
with corticotroph macroadenoma. 
Case report: 5 years ago in a 62-year-old patient the 
mass (24 x 33 x 28 mm) of the irregular shape loca-
ted in the Turkish saddle was visible. The hormonal 
studies revealed: ACTH 104.1 pg/mL (n < 63.6); 
normal cortisol diurnal rhythm and normal cortisol 
urine excretion but no inhibition neither during 
1mg DXM nor during both phases of Liddle’s test. 
He underwent an incomplete transsphenoidal ade-
nomectomy. In postoperative examination pituitary 
adenoma GH(–), PRL(–), ACTH(+), TSH(–), FSH(–), 
LH(–), alpha-subunit(–), MIB < 3% and in an elec-
tron microscope the sparsely granulated adenoma 
was found. After surgery, normal ACTH and proper 
pituitary function persisted for 22 months. Then a sli-
ght increase of ACTH was observed. One year later 
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ACTH increased to 86.3 pg/dL, the lack of the daily 
cortisol rhythm together with the lack of inhibition 
during 1mg DXM test and in MRI progression of the 
tumor residue were observed. 4 years after surgery 
ACTH 111.8 pg/mL, cortisol without circadian rhythm 
and further progression of tumor size were revealed. 
Currently ACTH is 136.5 pg/mL, cortisol circadian 
rhythm is incorrect, daily urine cortisol excretion is 
normal and tumor size in MRI 25 x 23 x 26 mm, but 
there are no evident clinical signs of hypercortisole-
mia until now. 
Conclusion: Subclinical Cushing’s disease caused by 
pituitary corticotropic macroadenoma may be clinically 
elusive for many years.
Pituitary tumors resistant to medical 
treatment: molecular and clinical aspects
E. Lavezzi1, N. Betella1, D. Milani2, A. Lania1, 3
1Endocrinology and Andrology Unit, Humanitas Research Hospital, 
Rozzano
2Neurosurgery Unit, Humanitas Research Hospital, Rozzano
3Department of Biomedical Sciences, Humanitas University, Rozzano,  
Italy
Despite the inhibitory effects on tumor growth and 
hormone secretion of DA agonists and somatostatin 
analogs (SSa), 10% of patients with PRLoma and 
30–40% of acromegalic patients are resistant to ca-
bergoline and to SSa, respectively. Generally, a re-
duced expression of functional DA and SS receptors 
in pituitary tumors has been associated with a poor 
response. In particular, this event has been clearly 
demonstrated in PRLomas. Conversely, though in 
vivo GH suppression and tumor shrinkage induced 
by SS analogs correlates with SSTR2 expression, 
some GHomas are resistant to therapy despite high 
SSTR2 expression. The molecular events responsible 
for reduced DRD2 and SSTRs expression are still 
largely unknown. In particular, while no mutation of 
the DRD2 gene has been found in resistant PRLomas, 
DA-resistance has been correlated only to a common 
DRD2 gene polymorphism. Interestingly, it has 
been recently demonstrated that filamin-A (FLNA), 
a widely expressed cytoskeleton protein with scaf-
folding properties, is crucial for D2R expression and 
signaling in lactotrophs, suggesting that the impaired 
response to DA may be related to the reduction of 
FLNA expression in DA-resistant PRLomas. Few data 
are available on possible DRD2 signal transduction 
alterations. In particular, it has been demonstrated 
the downregulation of TGF-β/Smad pathway in DA-
-resistant PRLomas compared to normal human an-
terior pituitaries. Similarly to DRD2, no mutations of 
SSTR2 and SSTR5 genes are usually found in resistant 
patients. Though polymorphic variants in SSTR2 gene 
seem to have no role in determining SS resistance of 
GHomas, a single SSTR5 gene polymorphism pre-
disposes to resistance to antiproliferative effects of 
SS, increased aggressiveness, and post-surgical reoc-
currence of pituitary tumors. Finally, the expression 
of a truncated variant of SSTR5 has been found to 
correlate with SS-resistance and tumor invasiveness 
possibly having a dominant-negative effect on SSTR2-
-mediated signaling.
Analysis of disorders of carbohydrate 
metabolism associated with newly diagnosed 
acromegaly
M. Lewicki1, M. Tyniec2, E. Obel3, J. Szydełko3,  
J.S. Tarach3, B. Matyjaszek-Matuszek3
1Chair and Department of Epidemiology and Clinical Research 
Methodology, Medical University of Lublin
2Independent Public Teaching Hospital No. 4 in Lublin
3Chair and Department of Endocrinology, Medical University of Lublin, 
Lublin, Poland
Introduction: Acromegaly is a rare endocrinopathy 
characterized by excessive production of hGH, with 
a corresponding increase in IGF-1 concentration. Both 
hGH and IGF-1 exhibit antagonism towards hypogly-
cemic action of endogenous insulin, leading to states 
of carbohydrate disorders.
The aim of the study was a retrospective analysis of 
the occurrence of carbohydrate metabolism disorders 
in patients with newly diagnosed acromegaly.
Material and methods: Retrospective analysis of 
available medical data of patients hospitalized in the 
Department of Endocrinology in 10 years period. The 
evaluation included 40 patients with newly diagnosed 
acromegaly before introduction of long-acting somato-
statin analogue therapy.
Results: 40 patients were included in the study: 
24 women and 16 men (60% vs 40%), 53.3 ± 11.8 years, 
BMI 31.6 ± 5.8 kg/m2 with mean IGF-1 740.9 ng/mL (Me: 
638.7). The carbohydrate disorders in the form of IFG 
were diagnosed in 17 patients (42.5%), IGT in 5 patients 
(12.5%) (double pre-diabetic status IFG+IGT in 3 pa-
tients). Diabetes most likely secondary to acromegaly 
was observed in 9 patients (22.5%). The mean HbA1c 
in the DM group was 5.8%.
Conclusions: IFG was the most common carbohydrate 
disorder associated with acromegaly. Carbohydrate 
metabolism disorders were not seen only in every 
third patient with newly diagnosed acromegaly. Co-
-occurring diabetes minimizes the utility of the key 
diagnostic test used in acromegaly: 75 g glucose hGH 
suppression. 
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Cyclic variant of ACTH-dependent Cushing’s 
syndrome. A case study
M. Lewicki1, E. Obel2, A. Smoleń1, B. Matyjaszek-
Matuszek2
1Chair and Department of Epidemiology and Clinical Research 
Methodology, Medical University of Lublin; Poland
2Chair and Department of Endocrinology, Medical University of Lublin, 
Lublin, Poland
Introduction: Cushing’s cyclic syndrome is characte-
rized by hypercortisolemia phases alternating with 
normocortisolemia, provided that no treatment has 
been introduced. Epidemiological data are not con-
sistent, estimating the frequency of a cyclic variant 
as 15–36%.
Case report: A 42-year-old female patient with ACTH-
-dependent Cushing’s syndrome due to microadeno-
ma, with typical phenotypic and metabolic features 
(secondary hypertension and insulin resistance). She 
was diagnosed 22 years ago (abnormal “fixed” daily 
rhythm of cortisol with elevated levels of cortisol). In 
the head CT performed at that time (October 25, 1995), 
the pituitary microadenoma was described, though no 
further diagnostic procedures were continued nor any 
treatment introduced. Many times the exacerbation of 
”cushingoid” symptoms with their gradual resolution 
were observed, despite lack of specific treatment. New 
MRI scan shows pituitary microadenoma (7 x 5 mm). 
Double hormonal evaluation, performed currently, one 
month apart, managed to capture the state of hyper-
cortisolemia with subsequent normalization of cortisol.
Conclusions: The possibility of a cyclic variant of Cu-
shing’s syndrome should be suspected in every patient 
with inconsistencies between clinical presentation 
and the results of the adrenocorticotroph axis evalu-
ation. The cyclic Cushing syndrome is characterized 
by a less dynamic capacity to generate complications 
of hypercortisolemia, than does the classic form of 
the syndrome.
Myokines, factors that increase the tissue 
insulin sensitivity
A. Litwiniuk, M. Kalisz, M. Chmielowska, L. Martyńska, 
E. Wasilewska-Dziubińska, W. Bik
Centre of Postgraduate Medical Education, Department of 
Neuroendocrinology, Warsaw, Poland
Introduction: Skeletal muscles account approximately 
for 40–50% of the total body weight, therefore constitute 
the largest organ in the human body. Exercise possesses 
positive benefits for the body composition, insulin sen-
sitivity, cardiovascular health and cognition. Moderate 
exercise has been shown to increase lifespan in rats, 
improve neuromuscular and neurological performance 
in mice, and to reduce hyperglycemia, hyperchole-
sterolemia and hypertension. Proteins expressed and 
released by contracting muscle that have autocrine, 
paracrine, and endocrine bioactivities are termed 
myokines. Interleukin-6 (IL-6), interleukin-8 (IL-8), 
interleukin-15 (IL-15), brain-derived neurotrophic fac-
tor (BDNF), leukemia inhibitory factor (LIF), fibroblast 
growth factor 21 (FGF21), irisin and myonectin (CTRP15) 
are amongst them. IL-6 can play an important role in 
the regulation of a low-grade inflammation generated 
during obesity. Muscle-derived IL-15 could play a role as 
an important mediator of anti-adipogenic and insulin-
-sensitizing effects of the endurance exercise.
The aim of our study was to determine the effect of 
IL-15-myokine on omentin and chemerin secretion 
from the rat adipose tissue explants.
Our results clearly showed that IL-15 resulted in enhanced 
expression and secretion of omentin and decreased secre-
tion of chemerin from the adipose tissue explants culture. 
Conclusions: Regular physical activity may be an 
important strategy to prevent progression of insulin 
resistance associated with metabolic disease. Moreover, 
regular physical activity contributes to a reduction of 
the visceral fat amount and improves tissue insulin 
sensitivity. 
Acknowledgments: This study was supported by CMKP 
grant No 501-1-31-22-17.
Neuroendocrine mechanisms in 
pathophysiology of heart failure
U. Mackiewicz, M. Mączewski
Department of Clinical Physiology, Center of Postgraduate Medical 
Education, Warsaw, Poland
Heart failure (HF) is a disease of ageing populations. Its 
prevalence increases with age and exceeds 10% in 
subjects above 70 years of age. Ischemic heart disease, 
including myocardial infarction and hypertension, 
are the most common causes of HF. They result in 
myocardial remodeling, reduced cardiac output and 
inadequate organs perfusion and in consequence signs 
and symptoms including dyspnea, edema and reduced 
exercise capacity.
Pathophysiology of HF is complex but chronic neuro-
endocrine activation (NEA) involving mainly activation 
of the sympathetic nervous system (SNS) and renin-
-angiotensin-aldosterone system (RAAS) is its principal 
factor. Furthermore, vasopressin release and synthesis 
of endothelins, proinflammatory cytokines and natriu-
retic peptides are enhanced.
Physiological concept behind NEA is to maintain car-
diovascular homeostasis under stress. Reduced number 
of functional cardiomyocytes as a result of ischemia or 
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hypertension triggers NEA as a compensatory mecha-
nism. Indeed, SNS and RAAS activation initially acts 
to maintain cardiac output by increasing contractility, 
heart rate, the circulating blood volume and constricting 
resistance arterioles.
However, NEA is programmed by the evolution for 
short term regulation and an organism is helpless 
when faced with negative effects of its prolonged 
action. If the detrimental or stressing stimulus for the 
cardiovascular system persists, adverse effects of long 
term NEA appear: hypertrophy, dilatation of cardiac 
chambers, fibrosis, arrhythmias as well as cellular and 
molecular remodeling. Indeed, chronic SNS and RAAS 
activation was shown to result in HF progression and 
eventually death.
An important confirmation of key role of NEA in the 
HF pathophysiology is provided by the fact that cur-
rent pharmacological treatment of HF that reduces 
mortality and slows the disease progression, involves 
restoration of the neuroendocrine balance through 
reduction of SNS overactivity, RAAS blockade at se-
veral levels and recently also through blockade of an 
endopeptidase that breaks down natriuretic peptides. 
Blood serum concentrations of gonadotropins 
in patients with gonadotropinomas in relation 
to the immunoreactivity of pituitary  
adenoma
M. Pawlikowski1, M. Jaranowska2, J. Fryczak1,  
M. Radek3, J. Świętosławski2, J. Kunert-Radek4,  
K. Winczyk2
1Department of Immunoendocrinology, Chair of Endocrinology, Medical 
University of Lodz, Poland
2Department of Neuroendocrinology, Interdepartmental Chair of 
Laboratory and Molecular Diagnostics, Medical University of Lodz, 
Poland
3Department and Chair of Neurosurgery and Surgery of Peripheral 
Nerves
4Department of Clinical Endocrinology, Chair of Endocrinology, 
Medical University of Lodz
Introduction: Although the active gonadotropin-se-
creting pituitary adenomas are considered as very 
rare, the vast majority of pituitary tumours diagnosed 
as „nonfuctioning” express gonadotropins or their 
free β or α subunits. However, the systemic investiga-
tions comparing the serum concentrations of folitro-
pin (FSH), lutropin (LH) and α-subunit (α-SU) before 
surgery with the immunoreactivity of the respective 
substances in the excised tumours are still lacking. 
Material and methods: Immunostaining of FSH, LH 
and α-SU was compared in 43 surgically removed go-
nadotropin — expressing pituitary adenomas with se-
rum concentrations of the above mentioned substances 
before surgery in the same patients. 
Results: The serum concentrations of FSH were elevat-
ed (> 10 mU/mL) in 8/12 (66.7%) cases of FSH-positive 
adenomas. In contrast, in FSH-negative tumours the 
elevation of FSH is absent. Moreover, only 1/25 (4%) 
patient with LH-positive adenoma had the elevated 
serum concentration of LH (51.5 mU/mL). The over-
secretion of LH was observed neither in adenomas 
expressing free β LH nor in LH-negative tumours. In 
patients with α-SU-positive adenomas the elevated 
serum levels of α-SU (> 1 mU/mL) were observed in 
3/15 (20%) cases. No α -SU elevations were observed 
in patients with α-SU-negative adenomas.
Conclusions: Although „silent” gonadotropinomas 
constitute a frequent subtype of pituitary adenomas, 
the „active” (i.e. manifesting by gonadotropin excess) 
are rare (approx. 4% of all pituitary adenomas). Go-
nadotropinomas are difficult to diagnose before sur-
gery. The measurement of gonadotropins including 
α-SU is needed but often not sufficient for presurgi-
cal diagnosis.
Nesfatin-1 is a novel modulator of stress 
response in rat
K. Pierzchała-Koziec1, C.G. Scanes2
1Department of Animal Physiology and Endocrinology, University of 
Agriculture in Krakow, Poland
2Center of Excellence in Poultry Science, University of Arkansas, USA
Nesfatin-1 is distributed in the stress-related brain 
regions including the hypothalamus and co-localized 
with stress-related hormones. It is also involved into 
regulation of over-feeding and modulation of obesity 
status often accompanied by inflammation. The objective 
of the study was to investigate whether the stressful 
immune-inflammatory response is a factor involved into 
association between nesfatin-1 and pituitary-adrenal 
axis in rat. Experiment was carried out on male Wistar 
rats divided into control, naltrexone, mannan and na-
ltrexone+mannan treated groups. The immune status 
was estimated by the Il-6 level and leucocytes number, 
stress reaction was measured by blood ACTH level and 
corticosterone concentration in the adrenal gland. The 
involvement of nesfatin-1 in the stress response was 
evaluated by the changes of this peptide level in the 
blood and hypothalamus. Mannan, serving as a proin-
flammatory factor, significantly increased the leucocytes 
number and Il-6 plasma level. Increased level of plasma 
ACTH in parallel with decreased concentration of corti-
costerone in adrenal gland proved the presence of stress 
response. Plasma level and hypothalamic concentration 
of nesfatin-1 reached the highest values 120 min after 
mannan injection. Interestingly, nesfatin-1 showed hi-
gher response also to the naltrexone, an opioid receptor 
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antagonist, what may suggest interaction of this peptide 
and opioids. Thus, the reaction of nesfatin-1 to the in-
flammation suggests its important role in the regulation 
of stress response at the central and peripheral levels. The 
hyperactivity of pituitary-adrenal axis associated with 
higher level of nesfatin-1 after naltrexone injection clearly 
indicates the opposite effect to the opioids regulation of 
stress reaction. 
Supported by the DS/DAPE/2017-2018.
Subclinical left ventricular systolic dysfunction 
in patients with naive acromegaly assessed 
by two-dimensional speckle tracking 
echocardiography (2D-STE)
A. Popielarz-Grygalewicz1, M. Stelmachowska-Banaś2,  
J. Gąsior1, 3, A. Konwicka1, P. Grygalewicz1,  
W. Zgliczyński2, M. Dąbrowski1
1Cardiology Clinic of Physiotherapy Division of the 2nd Faculty of 
Medicine, Medical University of Warsaw, Poland
2Department of Endocrinology, The Centre of Postgraduate Medical 
Education, Warsaw, Poland
3Faculty of Health Sciences and Physical Education, Kazimierz Pulaski 
University of Technology and Humanities, Radom, Poland
Introduction: Speckle tracking echocardiography (STE) 
is a novel method that allows for the study of global lon-
gitudinal strain (GLS), a marker of early and subclinical 
left ventricular (LV) systolic dysfunction. 
The aim of the study: To evaluate left ventricular GLS 
in patients with naive acromegaly with normal LV 
systolic function.
Material and methods: Fifty-one consecutive patients 
with naive acromegaly with normal systolic LV function 
measured by ejection fraction (EF), and a control group 
were matched for age and gender underwent 2D-STE.
Results: The mean GLS was lower in acromegalics 
than in the controls (in%, –17.28 ± 4.9 vs. –20.9 ± 3.2, 
p < 0.01). Majority of acromegaly patients (60.7%) had 
abnormal GLS. Patients with impairment in GLS had 
longer duration of acromegaly symptoms compared 
to those with normal GLS values (years, 10.0 vs. 5.0, 
p < 0.05). Acromegalics with lower GLS had also an 
increase in parameters of LV thickness i.e. IVS [in mm, 
13 (8–19) vs. 11.5 (8-14), p < 0.05] and PW [in mm, 
13 (8–17) vs. 12 (9–13) p < 0.05]. There was a nega-
tive correlation between LVMi and GLS (R = –0.38, 
p < 0.01).
Conclusions: Naive acromegalic patients presented 
with lower GLS compared to the control group which 
indicates subclinical systolic dysfunction in the untre-
ated acromegalic patients. We found longer disease 
duration in acromegalics with impairment in GLS 
compared to those with normal values. 
Cushing’s disease with cyclic occurrence of 
hypercortisolemia — a case report
D. Porada, M. Lenart-Lipińska, A. Szafraniec,  
B. Matyjaszek-Matuszek
Chair and Department of Endocrinology, Medical University of Lublin, 
Poland
Introduction: Cyclic Cushing’s syndrome is characte-
rized by alternating periods of hypercortisolemia and 
episodes of normal serum cortisol. The clinical picture 
may be ambiguous, which can cause difficulties in 
the diagnosis.
The aim of the study: Presentation of the diagnostic 
process of a patient with cyclic Cushing’s syndrome.
A case report: 28 year old female with metabolic 
syndrome (giant obesity, type 2/secondary diabetes, 
insulin resistance, hypertension, mixed hyperlipi-
demia, hyperuricemia), hyperandrogenism and 
hypercortisolemia observed in an outpatient setting. 
During many hospitalizations, hypercortisolemia, an 
inverted circadian rhythm of ACTH secretion and 
3–6 times increased excretion of cortisol in the 24-hour 
urine sample were observed. In the dexamethasone 
suppression tests, there was no suppression by low 
dose and full suppression by 8 mg dexamethasone. In 
the pituitary MRI, a focal lesion was described in the 
intermediate lobe (a small mucous cyst of the Rathke 
pouch or a cystic microadenoma). In a second study, the 
correct response to 2 mg dexamethasone was observed, 
and pseudo-Cushing syndrome was excluded with the 
CRH test. Periodic occurrence of cortisolemia and the 
results of functional tests, along with clinical symptoms 
and medical imaging, allowed for the diagnosis of cyclic 
Cushing’s syndrome most likely caused by a pituitary 
adenoma. The patient was referred for Inferior petrosal 
sinus sampling.
Conclusions: Differential diagnosis of Cushing’s syn-
drome is often complicated. Diverse medical signs of 
patients with cyclic Cushing’s syndrome, especially 
periods with normal cortisol levels, may lead to incor-
rect diagnoses.
BDNF — a central modulator of the GnRH/LH 
axis activity
B.J. Przybył, M. Szlis, A. Wójcik-Gładysz
The Kielanowski Institute of Animal Physiology and Nutrition, Polish 
Academy of Sciences, Department of Animal Physiology, Jablonna, 
Poland
Introduction: Neuropeptides involved in the regulation 
of food intake are often involved in the reproductive 
processes activity controlling. Brain-derived neuro-
trophic factor (BDNF) (belonging to neurotrophins 
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peptides family) is engaged in appetite regulation 
processes at the central nervous system level. 
The aim of this study was to verify the research hypo-
thesis, which assumes that BDNF can modulates the 
gonadotrophic axis secretory activity at the hypotha-
lamic-pituitary level in sheep. 
Material and methods: The experiment was performed 
on Polish Merino sheep (n = 24). Animals were divided 
into 3 groups and infusions into the III ventricle of 
the brain was performed: 1. Ringer-Locke solution 
480 μL/day; 2. BDNF in dose 10 μg/480 μL/day; 3. BDNF 
in dose 60 μg/480 μL/day. After the last infusion sheep 
were slaughtered, the selected structures of the brain 
and plasma samples were stored for Real Time RT qPCR 
and radioimmunoassay analysis.
Results: The obtained results showed that BDNF 
stimulate the expression of GnRH gene in the POA 
as well as GnRH-R in the pituitary. Exogenous BDNF 
stimulate also the LH gene and protein expression in 
the gonadotrophic pituitary cells. These changes led to 
increase in LH level in the blood plasma. 
Conclusions: Based on the presented results it can be 
concluded that BDNF may modulate the gonadotrophic 
axis activity in sheep.
The study was financed by National Science Centre, 
Poland, grant PRELUDIUM 9; no. 2015/17/N/NZ9/01110.
Transcriptome analysis of rat adrenocortical 
cells exposed to ACTH in vitro and in vivo
M. Rucinski, K. Jopek, M. Tyczewska, M. Szyszka,  
P. Celichowski, P. Milecka, L.K. Malendowicz
Department of Histology and Embryology, Poznan University of 
Medical Sciences, Poznan, Poland
The aim of the study was to analyse the expression of 
ACTH-stimulated adrenocortical cells genes in three 
experimental models: (1) primary adrenocortical cell 
culture (exposure for 24 h), (2) acute (1h) i.p. ACTH 
injection and (3) prolonged ACTH infusion for 48 h 
using microosmotic pumps. Studies were carried out 
using Affymetrix Rat Gene 2.1 ST Arrays. Obtained 
raw data were analyzed using bioinformatics tools 
based on the R programming language. The selection 
criteria of a significantly affected genes were based 
on a fold expression change > 1.5 and 10% FDR. 
The total number of DEG was distributed as follows: 
in vitro (up — 1180, down — 417 genes), in vivo 1h 
(up — 534, down — 485 genes), in vivo 48 h (up — 49, 
down — 53 genes). In order to demonstrate general 
similarities and differences in ACTH action on adrenal 
cells in the studied models, principal component ana-
lysis (PCA), correlation matrix and Venn diagram were 
performed. DEG sets were assigned to significantly 
enriched ontology terms using DAVID and GSEA 
bioinformatics tools. 
Our results confirm that ACTH causes very dynamic 
changes in transcriptional profile in rat adrenocortical 
cells. In case of acute administration of ACTH in vivo, 
these changes are similar to those observed in vitro. 
However, after prolonged infusion of ACTH, the 
transcriptional profile of adrenocortical cells changes 
significantly. Under these conditions, the number of 
differentially expressed genes is significantly lower.
This research was supported by the National Science 
Centre (Poland) allocated on the basis of the decision 
number DEC-2013/11/B/NZ4/04746.
Maternal brain adaptations in pregnancy 
to satisfy fetal needs and risk of adverse 
programming
J.A. Russell
Centre for Discovery Brain Sciences, University of Edinburgh, 
Edinburgh, Scotland UK 
Successful pregnancy requires adjustments to multi-
ple maternal homeostatic mechanisms governed by 
the maternal brain, to support survival, growth and 
development of the conceptus and placenta. Such 
adjustments constitute allostasis (stability or survival 
through change), and have a cost: allostatic load. In 
pregnancy allostasis is driven by ovarian, anterior 
pituitary, placental and feto-placental hormones 
acting on the maternal brain: e.g. relaxin stimulates 
vasopressin secretion, permitting blood volume 
expansion; prolactin (and placental lactogens) indu-
ces leptin resistance, increasing appetite and energy 
supply; allopregnanolone (AP, 5α-reduced neuroac-
tive progesterone metabolite), reduces hypothalamo-
-pituitary-adrenal (HPA) axis responses to stressors, 
conserving energy and protecting fetuses. AP is pro-
duced and acts in the nucleus tractus solitarii where 
5α-reductase gene (srd5a1) expression increases in 
pregnancy. Here, AP induces opioid inhibition of 
noradrenergic input to the stress axis, with up- or 
down-regulation of key neuropeptide and receptor 
genes. The expression of hundreds more genes is 
altered in the maternal brain in pregnancy. Allostatic 
changes in gene expression in the brain evidently 
involve epigenetic mechanisms (e.g. DNA methyla-
tion/demethylation, histone modifications, or micro 
(mi)RNAs — which regulate srd5a1 expression). There 
is sparse information about epigenetic changes in 
the maternal brain in pregnancy, but abundant data 
about epigenetic changes from early-life experience 
in offspring brains. 
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Many women carry an existing allostatic load into 
pregnancy, due to socio-economic circumstances, or 
obesity. These pregnancies have poorer outcomes, 
suggesting negative interactions between pre-pre-
gnancy and pregnancy allostatic loads: a bad start for 
a new life. Importantly, exposure of pregnant rats to 
a social stressor results in F1 offspring with abnormal 
metabolic and stress response phenotypes. Pregnancy 
in such F1 programmed females, without further stress, 
results in F2 progeny with abnormal stress responses. 
It will be necessary to probe gene expression changes, 
and epigenetic mechanisms in brains of F1 vs normal 
pregnant rats to gain insights into intergenerational 
transfer of programming. 
Supported by the BBSRC.
Prediction of growth hormone (GH) therapy 
effectiveness in children with GH deficiency  
— application of neural models
U. Smyczyńska1, J. Smyczyńska2
1Department of Biostatistics and Translational Medicine, Medical 
University of Lodz, Lodz, Poland
2Department of Endocrinology and Metabolic Diseases, Polish Mother’s 
Memorial Hospital – Research Institute, Lodz, Poland
Accurate prediction of growth hormone (GH) therapy 
effectiveness is an important issue in pediatric endo-
crinology. Multiple linear regression and empirical 
non-linear models have been previously used for this 
purpose. Artificial neural networks (ANN) allow detec-
tion of both linear and non-linear dependencies without 
assuming their character a priori. Neural models consist 
of input layer to which input (explanatory) variables 
are delivered, hidden layers that process the data and 
output layer which outputs the result of prediction. 
Among various ANN, multilayer perceptron presented 
to be optimal for prediction of response to GH therapy. 
Two models were constructed for children with GH de-
ficiency (GHD): predicting change in height SDS during 
1st year of treatment and predicting final height (FH) 
SDS. Starting from 17 (1st year model) and 20 (FH) po-
tential predictors, input cancellation algorithm reduced 
their number to 9 and 10 significant ones. Eliminated 
variables included GH peak after falling asleep and in 
stimulation tests, while IGF-I concentrations and earlier 
growth were the most important predictors. Average 
error of prediction was 0.25 SD (1st year) and 0.50 SD 
(FH); both models explained about 45% of variability. 
Majority of the dependencies among variables were 
non-linear. Neural models allow to obtain accurate 
height prediction for children with GHD, to select signi-
ficant predictors and to provide realistic, personalized 
expectations about treatment effects.
Modelling anorexia nervosa in rats
P. Stach, M. Kurnik-Łucka, K. Skowron, A. Baranowska, 
K. Gil
Department of Pathophysiology, Jagiellonian University Medical 
College, Krakow, Poland
Introduction: Anorexia nervosa (AN) is an eating disorder 
characterized by weight loss and difficulties in mainta-
ining an appropriate body weight. Rodents show a ten-
dency to self-starvation when exposed to a time-restricted 
feeding schedule and given the possibility of voluntary 
physical activity in a running wheel, and thus mimic AN.
The aim of the study was to establish the model of acti-
vity-based anorexia (ABA) in our laboratory investigating 
food intake, running wheel activity and body weight 
in rats. Only female rats were used due to the higher 
prevalence of anorexia in females compared to males.
Material and methods: Wistar rats weighing 170–220 g 
upon their arrival were housed in groups under con-
trolled conditions and were fed with standard rat chow 
(Labofeed B, Kcynia, Poland) and tap water ad libitum. 
This study was carried out in accordance with the in-
stitutional guidelines (65/2017). After an initial acclima-
tization period of 5 days, rats (n = 32) were randomly 
assigned to one of four groups (n = 8 each) with: (1) no 
extra activity + ad libitum feeding schedule, (2) volun-
tary activity in a running wheel + ad libitum feeding 
schedule, (3) no extra activity + restricted feeding sche-
dule, and (ABA group) voluntary activity in a running 
wheel + restricted feeding schedule. All cages contained 
environmental enrichment and bedding material, and 
were placed adjacent to each other to provide sight, 
acoustic and odor contact. Body weight, food intake 
and activity were monitored daily. The experiment was 
discontinued and animals euthanized when the body 
weight loss exceeded 25%. 
Results: ABA rats showed a reduced daily food intake 
and a significant reduction in body weight in comparison 
to other groups. Physical activity was also significantly 
increased in ABA rats in comparison to a voluntary 
activity in a running wheel + ad libitum feeding group.
Conclusions: The ABA model combines voluntary 
physical activity in a running wheel and time-restricted 
feeding to reduce body weight. Our data point the use-
fulness of the model to understand pathophysiological 
alterations occurring in AN.
Profiling of miRNA expression in sheep 
hypothalamus after BDNF treatment
M. Szlis, B.J. Przybył, A. Wójcik-Gładysz
The Kielanowski Institute of Animal Physiology and Nutrition, Polish 
Academy of Sciences, Department of Animal Physiology, Jabłonna, 
Poland
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Introduction: Brain-derived neurotrophic factor 
(BDNF) is growth factors protein, exhibiting neuromo-
dulatory action on the whole brain and may participate 
in modulation of the metabolic processes at the CNS 
level. Moreover, available studies have shown that 
BDNF participate in pathophysiological mechanisms 
of many diseases which disturb the body energy 
homeostasis. Because BDNF modulate the activity of 
NPY/AgRP and CART/αMSH neurons — which cre-
ate hypothalamic appetite–regulating centre, the aim 
of study was to profiling the expression of selected 
miRNAs (involved in post-transcriptional modulation 
of NPY, AgRP, CART and POMC mRNA expression) 
in hypothalamus.
Material and methods: The experiment was performed 
on Polish Merino sheep (n = 24). The following types of 
infusion into the third brain ventricle was performed: 
1. Ringer-Locke solution 480 μL/day; 2. BDNF in dose 
10 μg/480 μL/day; 3. BDNF in dose 60 μg/480 μL/day. 
After the last infusion sheep were decapitated and 
MBH was dissected to determine the expression of 
selected miRNAs.
Results: The presence of all investigated miRNAs in 
MBH from all experimental groups was confirmed. 
A dose dependent changes in: miRNA-33b-5p, miR-
NA-647, miRNA-647, miRNA-377-3p, miRNA-214-3p, 
miRNA-485 expression was observed. 
Conclusions: Summarizing BDNF may modulate selec-
ted miRNAs expression which one could be involved 
in post-transcriptional regulation of NPY/AgRP and 
CART/αMSH neurons activity. 
This research was partially supported by the founds 
provided by the National Science Centre, Poland, 
PRELUDIUM 9 grant no. 2015/17/N/NZ9/01110 and 
the ‘Start Grant’ funding by The Kielanowski Institute 
of Animal Physiology and Nutrition, Polish Academy 
of Sciences.
Prolactin/adenoma maximum diameter 
ratio as a predictor of clinical phenotype 
of prolactinomas and dopamine agonists 
treatment response — 5-years observation  
of a single-centre
J. Szydełko1, A. Szafraniec1, M. Lenart-Lipińska1,  
D. Porada1, D. Duma2, E. Obel1, M. Lewicki1,  
J. Karpińska1, J.S. Tarach1, B. Matyjaszek-Matuszek1
1Department of Endocrinology, Medical University of Lublin, Poland
2Department of Laboratory Diagnostics, Medical University of Lublin, 
Lublin, Poland
Introduction: Prolactinomas are the most common 
hormone secreting pituitary adenomas and they 
constitute 40% of all pituitary tumors. So far, there 
are not clinical, biochemical and imaging criteria with 
sufficient predictive value for evaluation of their clini-
cal phenotypes and response for dopamine agonists 
treatment. 
The aim of this retrospective study was to explore the 
connection between prolactin/adenoma maximum 
diameter (PRL/MD) ratio and clinical phenotype of 
prolactinomas at the diagnosis and after treatment.
Material and methods: 68 patients (38 male), aged 
17–78 years with newly diagnosed prolactinomas 
hospitalized in the Department of Endocrinology, 
Medical University of Lublin, between May 2013 and 
May 2018 were retrospectively analyzed. 17 patients 
had microprolactinoma and 51 macroprolactinoma. 
The correlation between PRL, PRL/MD ratio and hy-
perprolactinemia-related symptoms, adenoma mass 
effects and hypopituitarism were evaluated. 
Results: It has been observed that the initial value of 
the PRL/MD ratio did not affect the change in tumor 
size after treatment. Such a relationship has been 
demonstrated only in case of initial levels of PRL 
(p = 0.015) and the dose of bromocriptine (p = 0.031). 
There was statistically significant correlation between 
the PRL/MD ratio and occurrence of symptoms of 
prolactinomas such as sexual dysfunction (p = 0.015) 
and fatigue (p = 0.004). PRL/MD ratio was strongly 
positively associated with a dose of DA during follow-
-up period.
Conclusions: The results suggest that prolactin/adeno-
ma maximum diameter ratio may predict clinical phe-
notype of prolactinomas better than baseline prolactin 
level and tumor size separately. However, analyzed 
group of patients is too small to achieve significance. 
Therefore, further studies are necessary.
Neural networks as a tool for prognosis of the 
results of therapies
R. Tadeusiewicz
AGH University of Science and Technology, Krakow, Poland
Neural networks become very popular as a tool for mo-
delling of numerous systems — technological, econo-
mical, sociological, psychological and even political. On 
the other hand neural networks are models of neural 
structures and neural processes observed in real brain. 
However, for modelling of real neural structures and 
real neural processes occurring in living brain neural 
networks they are too simple. Nevertheless neural 
networks can be used for modelling behavior of many 
biological systems and structures. Such models are not 
useful for explaining biological systems and processes 
but can be very useful for analysis of such systems’ be-
havior including prognosis of future results of selected 
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activities, e.g., prognosis of results of different therapies 
for modelled illnesses. In this paper general information 
about neural networks principles, structures, functions, 
learning and applications are presented. Practical use 
of neural network as a tool for particular application 
(prediction of growth hormone therapy effectiveness) 
will be presented in next paper by Dr. Urszula Smy-
czynska. In this paper only the general methodology of 
such modelling is presented. Thanks to this, the content 
contained in this paper can be used by many doctors 
to predict the effects of many different therapies. Most 
important factors, determining success of every neural 
network application, are selection of input data for 
the model, designing od proper neural network type 
and structure, collecting learning set, performing the 
learning process, and wise interpretation of answers 
given by the network. All such items will be discussed 
in the lecture. 
Influence of pituitary gonadotropins, prolactin 
and growth hormone on expression of AQP5 in 
the porcine ovarian follicular cells
D. Tański1, Ł. Jaśkiewicz2
1Department of Anatomy and Animal Physiology, University of 
Warmia and Mazury in Olsztyn, Olsztyn, Poland
2Department of Human Physiology, University of Warmia and Mazury 
in Olsztyn, Olsztyn, Poland
Introduction: Aquaporins (AQPs) are proteins inte-
grated with the cell membranes that form selective 
channels to water and other molecules. 
The aim of the present study was to examine the effect 
of luteinizing hormone (LH), follculotropic hormone 
(FSH), prolactin (PRL) and growth hormone (GH) on 
AQP5 expression in granulosa (Gc) and theca (Tc) cells. 
Material and methods: The cell culture were incubated 
with experimental factors. Gene and protein expression 
was evaluated by qPCR, Western blot and immunoflu-
orescence. All numerical data were analyzed by one-
-way ANOVA and Tukey post hoc test. 
Results: The results showed that GH decreased 
expression of Aqp5 in Gc from middle follicles in 
relation to control. Increased expression of Aqp5 in 
Tc from large follicles was indicated by GH and PRL 
in relation to control. Significantly higher expression 
of AQP5 protein in Gc from middle and large follicles 
was indicated by FSH and PRL in relation to control. 
In co-cultures increased expression of Aqp5 was obse-
rved in Gc from large follicles incubated with LH, PRL 
and GH in relation to control. Significantly increased 
expression of Aqp5 was observed in co-cultures of Tc 
from all type of follicles incubated with LH, whereas 
PRL stimulated expression of Aqp5 in Tc from middle-
-sized follicles. 
Conclusions: These present results, has provided some 
novel insights into the regulation of AQP5 present in 
granulosa and theca cells of porcine ovarian follicles, 
suggest that pituitary gonadotropins, PRL and GH may 
mediate the action of AQP5.
This study was financed by NSC grant 2013/09/B/NZ9/ 
/03129.
The effect of anandamide on LH secretion from 
sheep anterior pituitary explants — ex vivo 
study
M. Tomczyk1, A.P. Herman1, J. Bochenek1,  
D. Tomaszewska-Zaremba2
1Department of Genetic Engineering, The Kielanowski Institute 
of Animal Physiology and Nutrition, Polish Academy of Sciences, 
Jabłonna, Poland
2Department of Animal Physiology, The Kielanowski Institute of 
Animal Physiology and Nutrition, Polish Academy of Sciences, 
Jabłonna, Poland
Introduction: Cannabinoids as well as endocannabino-
ids (ECBs) interfere in the neuroendocrine control of 
reproduction influencing GnRH/LH secretion. Besides 
the effect in the hypothalamus, still controversial is the 
direct activity of ECBs on the pituitary. 
The present study was designed to determine the 
effect of endocannabinoid — anandamide (ANA) on 
LH secretion from the anterior pituitary (AP) explants 
collected from anestrous ewes. 
Material and methods: The ex vivo experiment was 
carried out on the tissues collected from adult, 3-year 
old, Blackhead ewes (n = 6) in anestrous period. The 
AP were dissected and divided into 4 explants. The ex-
plants from each ewe were treated with: 1) M199 only, 
2) GnRH, 3) ANA and 4) GnRH + ANA and incubated 
for 3 h at 37°C (87% O2, 5% CO2). The LH concen-
tration in collected medium was assayed by RIA 
method and LHβ gene expression in the AP explants 
by Real-Time PCR method. Data were analyzed us-
ing the two-way ANOVA followed the Fisher ’s least 
significance test. 
Results: The results clearly showed that in the AP 
explants GnRH treatment stimulated (P < 0.05) the 
LHβ gene expression and in the explants co-incubat-
ed with GnRH, anandamide suppressed (P < 0.05) 
stimulatory effect of GnRH on the LHβ gene expres-
sion. The anandamide treatment also suppressed 
(P < 0.05) the stimulatory effect of GnRH treatment 
on LH release. 
Conclusions: These ex vivo results suggest that endo-
cannabinoid anandamide may influence reproductive 
processes acting at the pituitary level suppressing 
LH secretion.
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Immunohistochemical detection of 
somatostatin and dopamine receptors in 
pituitary adenomas from patients with 
acromegaly
J. Toszek1, M. Pawlikowski2, H. Pisarek1, M. Jaranowska1, 
E. Wojtczak1, K. Winczyk1
1Department of Neuroendocrinology, Interdepartmental Chair of 
Laboratory and Molecular Diagnostics, Medical University of Lodz, 
Poland
2Department of Immunoendocrinology, Chair of Endocrinology, Medical 
University of Lodz, Poland
Introduction: In acromegaly, pharmacotherapy is 
an important additional, or sometimes alternative, 
method of treatment for the surgical removal of the 
pituitary tumor. Nowadays, in accordance with re-
commendations, long-acting somatostatin analogues 
acting mainly via somatostatin receptor type 2 are used 
as first-line drugs. Sometimes, agonists of dopamine 
D2 receptor (DR2) are applied. However, some patients 
with acromegaly are resistant to these drugs. So for 
effective treatment, an exact profile of the receptors 
present in pituitary adenomas is needed, as well as 
other medications.
The aim of the study was to identify the somatostatin 
and dopamine receptors in pituitary tumors from 
patients with acromegaly.
Material and methods: Specific receptor antibodies 
were used to immunohistochemically determine the 
expression of all somatostatin receptors (SSTR1-5), 
and dopamine DR2 and DR4 receptors, in 21 pituitary 
tumors. DR4 belongs to the family of D2-like receptors 
and has a partially homologous structure to DR2. 
Results: SSTR1 expression was noted in 18 tumors, 
SSTR3 in 17 and SSTR5 in 16. SSTR2 was detected in 
only 14 samples. No SSTR4 expression was observed. 
A positive reaction with anti-DR2 antibodies occurred 
in seven tumors, and a reaction to anti-DR4 antibo-
dies in 14 samples. In two cases negative for SSTR2, 
the dopamine D2 receptor was observed. Moreover, 
one case demonstrated a positive reaction with anti-
-DR4 antibodies, but no reaction with any somatostatin 
receptors or DR2. Both somatostatin and dopamine 
receptors exhibited cytoplasmic or membrane loca-
lizations.
Conclusion: The lack of somatostatin receptors and 
the presence of dopamine receptors in pituitary tu-
mors justifies their treatment with dopamine agoni-
sts. However, the influence of DR4 expression on the 
effectiveness of dopamine agonists requires further 
detailed studies. The immunohistochemical evaluation 
of somatostatin and dopamine receptors in pituitary 
adenomas may allow appropriate pharmacological 
therapy to be chosen in patients with acromegaly.
This study was supported by Medical University of 
Lodz grant 503/5-020-02/503-51-001-17.
Valproate (VPA and levetiracetam (LEV) affect 
gonadotrope genes mRNA expression in 
anterior pituitary gland of rat ex vivo
E. Wasilewska-Dziubińska1, J. Marynowska3,  
A. Litwiniuk1, M. Zielińska-Górska4, M. Kalisz1,  
L. Martyńska1, M. Chmielowska1, A. Gajewska2
1Department of Neuroendocrinology, Centre of Postgraduate Medical 
Education, Warsaw, Poland
2Department of Animal Physiology, The Kielanowski Institute of 
Physiology and Animal Nutrition PAS, Jabłonna n. Warsaw, Poland
3Independent Team of Public Works Outpatient, Piaseczno n. Warsaw, Poland
4Faculty of Animal Science, Warsaw University of Life Sciences, 
Warsaw, Poland
Introduction: VPA and LEV a potent antiepileptic drugs 
has been claimed to induce reproductive disturbances 
in man. Although mechanisms responsible for VPA and 
LEV effects on reproductive axis activity are not fully 
recognized, existing data suggest both gonadal and 
hypothalamo-pituitary sites of VPA and LEV action. In 
previous study we reported that both drugs suppressed 
only GnRH — stimulated but not the basal LH release 
from anterior pituitary cells in vitro. VPA was reported 
to repress CnRHR-1 transcription in GnRH neuronal 
GT1-7 cell-line and inhibited synthesis of GnRH. 
The aim of the study was to determine whether VPA 
and LEV modulate GnRHR, LHβ, FSHβ mRNA expres-
sion in anterior pituitary gland of rat ex vivo. 
The experiment was conducted on anterior pituitary 
explants from the anterior pituitary of male 3 month-old 
the rat. Explants were stimulated for 3h with GnRH 
(1 μM), VPA (10 mM), LEV (10 mM) GnRH + VPA, 
GnRH + LEV. Total RNA was isolated according to 
standard methods and specific genes mRNA expression 
was assessed using qRT-PCR method. The reference 
gene was GAPDH.
Results: VPA and LEV inhibited the GnRH-stimulated 
increase of GnRH-R and FSHβ mRNA expression 
whereas stimulated the expression of mRNA for LHβ 
mRNA were significantly elevated in response to VPA 
and LEV treatment.
Conclusion: VPA and LEV antiepileptic drugs speci-
fically affect transcriptional gonadotropic activity via 
direct action exerted at the pituitary level. 
This study was financed by CMKP grant 506-1-31-01-15.
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Expression of dopamine receptors 4 in 
clinically nonfunctioning pituitary adenomas
K. Winczyk1, J. Toszek1, A. Sikora1, E. Wojtczak1,  
J. Świętosławski1, M. Pawlikowski2
1Department of Neuroendocrinology, Interdepartmental Chair of Laboratory 
and Molecular Diagnostics, Medical University of Lodz, Poland
2Department of Immunoendocrinology, Chair of Endocrinology, Medical 
University of Lodz, Poland
Introduction: Clinically non-functioning pituitary 
adenomas (CNFPA) are tumors that do not induce 
clinical symptoms of hyperpituitarism or any incre-
ase in the level of pituitary hormones. The pharma-
cological treatment of CNFPA is used when contra-
indications for surgery or recurrence of the tumor 
occur. Currently, somatostatin analogs are applied, or 
sometimes the dopamine agonists bromocriptine or 
cabergoline acting through the dopamine receptor 2, 
are used but their effectiveness is insufficient. Recen-
tly, dopamine receptors 4 (DR4) have been identified 
in normal cells of pituitary; these belong to the D2-
-like receptor family and are partially homologous to 
DR2. However, as the presence of DR4 in malignant 
cells has only so far been described in isolated ca-
ses. The present study investigates the occurrence of 
DR4 receptors in clinically non-functioning pituitary 
adenomas (CNPA).
Material and methods: Thirty-nine human clinically 
hormonally-inactive pituitary adenomas were exami-
ned. The immunohistochemical evaluation identified 
the following hormonal phenotypes for the tumors: 
18 plurihormonal adenomas, 17 gonadotropinomas, 
two corticotropinomas, one thyreotropinoma and 
one null-cell adenoma. DR4 were visualized by immu-
nohistochemistry using rabbit polyclonal anti-human 
antibody. 
Results: Positive immunostaining to DR4 was shown in 
33/39 pituitary adenomas. Dopamine receptors were lo-
cated in the cell membrane, as well as in the cytoplasm of 
tumor cells. Among plurihormonal adenomas, a positive 
reaction for the anti-DR4 antibody (most often mem-
brano-cytoplasmic) was observed in 16/18 cases and 
in gonadotropinomas, positive immunostaining (more 
commonly cytoplasmic) was found in 14/17 tumors. In 
other adenomas, DR4 occurred only in the cytoplasm. 
Conclusion: Our studies have shown that CNFPA 
cells possess DR4 both in the cell membrane and in 
the cytoplasm. However, to determine whether the 
expression of DR4 may improve the effectiveness of 
pituitary adenomas pharmacotherapy, such as the 
currently used dopamine analogues, further detailed 
studies are needed.
This study was supported by Medical University of 
Lodz grant 503/5-020-02/503-51-001-17.
Central injection of neostigmine diminishes 
lipopolysaccharide-induced suppression 
of GnRH/LH secretion in ewes during the 
follicular phase of the estrous cycle
M. Wójcik1, D. Tomaszewska-Zaremba2, J. Skipor3,  
A. Krawczyńska1, A. Antushevich1, J. Bochenek1,  
B. Pawlina1, K. Wojtulewicz1, A.P. Herman1
1Department of Genetic Engineering, The Kielanowski Institute of  
Animal Physiology and Nutrition, Polish Academy of Sciences, 
Jabłonna, Poland
2Department of Animal Physiology, The Kielanowski Institute of 
Animal Physiology and Nutrition, Polish Academy of Sciences, 
Jabłonna, Poland
3Department of Local Physiological Regulations, Institute of Animal 
Reproduction and Food Research of the Polish Academy of Sciences in 
Olsztyn
The study was designed to determine whether the 
central injection of neostigmine, reversible inhibitor of 
acetylcholinesterase (AChE), will suppress lipopolysac-
charide (LPS)-induced synthesis of interleukin (IL)-1β 
in the hypothalamus and reduce the effect of immune 
stress on gonadotropin-releasing hormone (GnRH) and 
luteinizing hormone (LH) secretion. 
Material and methods: The in vivo experiment was 
performed on 4 groups (n = 6) of ewes: control (sa-
line, i.v.), neostigmine-treated (1 mg/animal, i.c.v.), 
LPS-treated (400 ng/kg, i.v.), and neostigmine- (i.c.v.) 
and LPS- (i.v.) treated during the synchronized fol-
licular phase. The animals were injected with neo-
stigmine/Ringer ’s solution 0.5 h prior to LPS/saline 
treatment and then euthanized 3 h after LPS/saline 
treatment. The concentration of LH in blood was as-
sayed by RIA. The content of GnRH in the hypothala-
mus was determined by ELISA. The gene expressions 
of GnRH, LHβ, IL-1β and IL-1 receptors were assayed 
by Real-Time PCR.
Results: Neostigmine injection not only abolished sup-
pressive effect of LPS on GnRH and LH secretions, but 
animals injected with LPS and neostigmine showed 
higher circulating level of LH in competition to control 
group. At least partially, this effect of neostigmine treat-
ment may result from inhibition of IL-1β synthesis in 
the hypothalamus. 
Concluding, the study showed that central injection of 
neostigmine effectively diminished the negative effect 
of inflammation on GnRH/LH secretion in ewes.
This work was supported by the funds granted by Na-
tional Science Centre, decision no DEC-2013/11/B/NZ9/ 
/01848.
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BDNF — possible action on the somatotrophic 
axis activity
A. Wójcik-Gładysz, M. Szlis, B.J. Przybył
Department of Animal Physiology, The Kielanowski Institute of Animal 
Physiology and Nutrition, Polish Academy of Sciences, Jabłonna, Poland
Introduction: Brain-derived neurotrophic factor 
(BDNF) is one of the growth factors protein belonging 
to neurotrophins peptides family. Neuromodulatory 
action of BDNF at the CNS level is connected with the 
regulation of the metabolic and energy intake proces-
ses. Therefore it is probable, that BDNF can participates 
in the regulation of growth and development processes 
which are dependent on the organism energy status. 
The aim of this study was to verify the research hypo-
thesis, which assume that BDNF can modulate soma-
totrophic axis activity in sheep. 
Material and methods: The experiment was performed 
on sexually mature Polish Merino sheep (n = 24). 
Animals were divided into 3 groups. The following 
intracerebroventricular infusions were performed: 
control group (Ringer-Locke solution), group I (BDNF 
in dose 60 μg/480 μL/day), and group II (BDNF in dose 
10 μg/480 μL/day). After the experiment animals were 
slaughtered and the selected structures of the hypothal-
amus, pituitaries were stored for Real Time RT qPCR. 
Central infusion of BDNF evoked the dose-dependent 
changes in srif and ghrh mRNA expression. 
Results: The obtained result show an increase in SRIF 
mRNA expression in AHA and in GHRH mRNA expres-
sion in MBH. Moreover, changes in Gh, GHRH-R, SRIF-R 
mRNA expression in the pituitary cells were noted. 
Conclusions: The results obtained so far suggest that 
BDNF is engaged in growth processes regulation at the 
central nervous system level.
This research was partially supported by the founds provi-
ded by the National Science Centre, Poland, PRELUDIUM 
9 grant no. 2015/17/N/NZ9/01110 and by founds provided 
by the Ministry of Sciences and Higher Education, Poland.
Association between thyroid-stimulating 
hormone and metabolic parameters in 
euthyroid patients with polycystic ovary 
syndrome
N.B. Zawada
Department of Clinical Endocrinology, Medical University of Lodz, 
Poland
Introduction: Polycystic ovary syndrome (PCOS) is cha-
racterized by oligo- or anovulation, hyperandrogenism 
and insulin resistance. Moreover, it is associated with 
higher risk of diabetes mellitus and dyslipidemia. Some 
data also suggest higher prevalence of autoimmune 
thyroid disorders in PCOS patients. 
The aim of the study: To assess the relationship be-
tween thyroid-stimulating hormone (TSH) levels and 
metabolic parameters in euthyroid patients with PCOS. 
Material and methods: The study enrolled 28 euthyroid 
patients with diagnosed PCOS on the basis of Rot-
terdam criteria. Exclusion criteria were: history of thy-
roid disorders, diabetes mellitus, hyperprolactinemia, 
Cushing’s syndrome, congenital adrenal hyperplasia, 
pregnancy and medications that can alter TSH levels 
or lipid profile. Lipid profile and oral glucose tolerance 
test with calculation of HOMA index were performed 
in each case. PCOS patients were divided according 
to TSH concentrations into 2 subgroups: subgroup 
A — low normal range TSH (0.27–2.49 μIU/mL) and 
subgroup B — high normal range TSH (2.5–4.2 μIU/mL).
Results: Subgroup A was characterized by lower levels 
of low density lipoproteins, triglyceride and higher 
levels of high density lipoproteins than subgroup B. 
Moreover, lower levels of fasting insulin were observed 
in subgroup A compared to subgroup B. Fasting glucose 
concentrations were comparable in both subgroups 
while HOMA index was significantly lower in subgroup 
A (1.69 ± 0.23 vs. 2.02 ± 0.28). 
Conclusions: Upper normal limit TSH concentration is 
associated with worse lipid profile and higher insulin 
resistance index in euthyroid PCOS patients. Therefore, 
a cut-off value for TSH < 2.5 μIU/mL should be estab-
lished for PCOS patients, especially for those with other 
risk factors of cardiovascular diseases. 
The role of somatostatin analogues and 
dopamine agonists in the postsurgical 
management of non-functioning pituitary 
adenomas
N.B. Zawada, J. Kunert-Radek
Department of Clinical Endocrinology, Medical University of Lodz, 
Poland
Introduction: Surgery, which remains the first-line tre-
atment of invasive non-functioning pituitary adenomas 
(NFPA), is rarely curative, leaving tumour remnant that 
can regrow in a significant proportion of cases. Postsur-
gical management of NFPA is not clear, however, some 
data suggest that somatostatin analogues (SSA) and do-
pamine agonists (DA) could be effective in preventing 
residual tumour progression.
The aim of the study: To assess the efficacy of SSA 
and/or DA on tumour volume and visual field (VF) in 
patients with NFPA after incomplete surgery. 
Material and methods: Twenty-eight patients not cu-
red by surgery were treated with either SSA (8 patients 
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— octreotide 20 mg intramuscular or lanreotide auto-
gel 120 mg subcutaneously every 28 days), DA (10 pa-
tients — bromocriptine 2.5–5 mg daily or cabergoline 
1–2 mg weekly) or with combined therapy with SSA 
and DA. The presence of somatostatin receptors in 
scintigraphy and immunohistochemistry was a sine 
qua non condition to start SSA therapy. The follow-up 
period varied from 18 months to 20 years. Adenoma 
size was evaluated in pituitary magnetic resonance 
imaging while VF tests were assessed by experien-
ced ophthalmologists.
Results: We observed tumour progression in respecti-
vely 22.2% patients treated with SSA and 40% patients 
given DA. None of these patients showed regression of 
the adenoma. Considering combined therapy, tumour 
progression was noticed in 33.3% cases, however, 22.2% 
patients achieved tumour shrinkage. Enlargement 
of tumour size was associated with VF deterioration, 
albeit tumour shrinkage did not correspond to VF 
improvement. 
Conclusions: DA are not more effective than SSA 
in the postsurgical management of NFPA. However, 
combination of both agents seems to be the most ef-
fective strategy, giving hope for tumour shrinkage in 
some cases. 
Tumour progression in clinically non- 
-functioning pituitary adenomas — does 
somatostatin analogue therapy decrease the 
risk?
N.B. Zawada1, J. Kunert-Radek1, M. Radek2
1Department of Clinical Endocrinology, Medical University of Lodz, 
Poland
2Department of Neurosurgery & Surgery of Peripheral Nerves, Medical 
University of Lodz, Poland
Introduction: The management of clinically non-func-
tioning pituitary adenomas (NFPA) remains a debated 
issue. Surgery, which is indisputably indicated in 
invasive NFPA, is rarely curative. Moreover, it is not 
always feasible due to potential complications or con-
traindications. Expression of somatostatin receptors 
(SSTR) form the rationale for the use of somatostatin 
analogues (SSA) in NFPA.
The aim of the study: To compare the risk of NFPA pro-
gression in patients treated with SSA vs. those without 
pharmacotherapy. 
Material and methods: 57 patients with NFPA (subgro-
up A-40 after incomplete surgery + subgroup B-17 not 
operated) were enrolled into the study. SSTR scinti-
graphy and additionally immunohistochemistry (sub-
group A) were performed. The presence of SSTR was 
confirmed in 25 patients (17 from subgroup A+8 from 
subgroup B) in whom SSA therapy was started (every 
4 weeks: octreotide LAR 20 mg intramuscular or lan-
reotide autogel 120 mg deep subcutaneous injection). 
The duration of the therapy varied from 16 months 
to 18 years. Adenoma size was estimated in pituitary 
magnetic resonance imaging. 
Results: Tumour progression rate was twice higher in 
patients who were not treated with SSA (71.9% vs. 36%). 
In subgroup A tumour volume increased in 35.3% pa-
tients treated with SSA compared to 74% those without 
pharmacotherapy. Moreover, in subgroup B tumour 
progression was noticed in 37.5% SSA treated patients 
vs. 66.7% not SSA treated patients. 
Conclusions: SSA significantly decrease the probability 
of tumour progression in NFPA, however, further stu-
dies should be carried out. 
What is new in acromegaly?
W. Zgliczyński
Centre of Postgraduate Medical Education, Warsaw, Poland
Acromegaly is a rare chronic disease caused by growth 
hormone hypersecretion (GH), mostly (99%) by pitu-
itary adenomas (> 70% macroadenomas). Acromegaly 
leads to altered appearance (enlargement of the facial 
bones, hands and feet), bones, soft tissues and internal 
organs hyperplasia, and many comorbidities which re-
sult in reduction in length and quality of life. In percent 
of cases acromegaly has genetic causes: multiple endo-
crine neoplasia type 1, Mc-Cune Albright syndrome, 
familial acromegaly and Carney’s syndrome, aryl hy-
drocarbon receptor interacting protein gene mutations, 
X-LAG caused by microduplications on chromosome 
Xq26.3 encompassing the gene GPR101. In those cases 
the course of the disease is altered, with mostly aggres-
sive tumours, which often do not respond to pharma-
cological treatment. The biochemical confirmation of 
acromegaly includes GH and IGF-1 assays. However, in 
¼ patients there are discrepancies, due to the occurrence 
of heterophile antibodies, or anti-GH and anti-IGF-1 an-
tibodies which cause difficulties in the interpretation of 
the results. Treatment of acromegaly includes surgery, 
radiotherapy and medical treatment (somatostatin 
analogues, pegvisomant, dopamine receptor agonists). 
While 1st generation somatostatin analogues are effec-
tive in 40 percent cases, it comes out that a new agent: 
2nd generation somatostatin analogue, pasireotide, is 
effective in 20 percent patients who do not respond to 
1st generation somatostatin analogues. Pasireotide has af-
finity for many somatostatin receptors, especially SSTR5.
Lecture sponsored by Novartis
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The effect of the hypothalamo-pituitary-adrenal 
hormones on adiponectin gene expression 
during inflammation in in vitro condition
J. Zubel-Łojek, K. Pierzchała-Koziec, E. Ocłoń,  
A. Latacz
Department of Animal Physiology and Endocrinology, University of 
Agriculture in Krakow, Krakow, Poland
Introduction: It is recognized that the adipose tis-
sue produces multiple peptides, called adipokines, 
which play a significant role in the pathogenesis of 
a low-grade inflammation associated with obesity 
and metabolic syndrome. Also, they are involved into 
regulation of chronic inflammatory and autoimmune 
diseases. Among variety of adipokines, adiponectin is 
proposed as important anti-inflammatory mediator. 
Chronic stress characterized by prolonged alteration 
in the hypothalamo-pituitary-adrenal (HPA) axis and 
additionally combined with positive energy balance, 
may be a contributor to the increased risk for obesity. 
Thus, the present study aimed to examine the effect of 
exogenous HPA hormones on the expression of adipo-
nectin in the cultured adipocytes during inflammation 
induced by TNF-alpha. 
Human adipocytes cultured in specific medium were 
treated with CRH, ACTH and glucocorticoids alone or 
together with TNF-alpha for 24 h, than the adiponectin 
mRNA was expressed quantitatively by real-time PCR.
TNF-alpha alone strongly increased adiponectin mRNA 
levels after 24 h (P < 0.01). Both hormones, CRH and 
ACTH, increased adipokine mRNA expression, in contrast 
glucocorticoids did not changed the adiponectin expres-
sion. Interestingly, in TNF-alpha presence HPA hormones 
decreased expression of adipokine after 24 h (P < 0.01). 
Obtained results indicate, that the effect of stress hor-
mones on the synthesis of adiponectin in adipocytes 
depends on inflammatory status. 
Supported by: grants from NCN (NN 311 227 138) and 
DS 3243/KFiEZ.
